<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02628444</url>
  </required_header>
  <id_info>
    <org_study_id>CYD65</org_study_id>
    <secondary_id>U1111-1161-3242</secondary_id>
    <secondary_id>2020-002854-25</secondary_id>
    <nct_id>NCT02628444</nct_id>
  </id_info>
  <brief_title>Immunogenicity and Safety of Different Vaccination Schedules of Tetravalent Dengue Vaccine in Healthy Subjects 9 to 50 Years of Age</brief_title>
  <official_title>Immunogenicity and Safety of Tetravalent Dengue Vaccine Given in 1-, 2-, or 3- Dose Schedules (STAGE I) Followed by a Single Booster Injection of the Same Vaccine (STAGE II) 1 or 2 Years After the Last Primary Dose in Healthy Subjects 9 to 50 Years of Age in Colombia and the Philippines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study was to assess the immune response and the safety of different&#xD;
      vaccination schedules of CYD dengue vaccine.&#xD;
&#xD;
      The primary objectives of the study were:&#xD;
&#xD;
        -  To demonstrate the non-inferiority of the immune response elicited against each dengue&#xD;
           serotype by CYD dengue vaccine given as a 2-dose schedule (Group 2) compared to the&#xD;
           immune response elicited by CYD dengue vaccine given as a 3-dose schedule (Group 1), in&#xD;
           previously dengue exposed participants 28 days after the last injection.&#xD;
&#xD;
        -  To demonstrate the non-inferiority of the immune response elicited against each dengue&#xD;
           serotype by CYD dengue vaccine given as a 2-dose schedule (Group 2) compared to the&#xD;
           immune response elicited by CYD vaccine given as a 3-dose schedule (Group 1) in&#xD;
           previously dengue exposed participants, 1 year after the last injection.&#xD;
&#xD;
        -  To demonstrate the non-inferiority of the immune response elicited against each dengue&#xD;
           serotype elicited by a booster dose of CYD dengue vaccine one year or two years after&#xD;
           the last injection in the primary series in previously dengue exposed participants,&#xD;
           compared to the immune response post dose 3 in Group 1.&#xD;
&#xD;
      The secondary objectives of the study were:&#xD;
&#xD;
        -  To demonstrate the superiority of the immune response elicited by CYD dengue vaccine&#xD;
           given as a 2-dose schedule (Group 2) compared to the immune response elicited by CYD&#xD;
           dengue vaccine given as a 3-dose schedule (Group 1), in previously dengue exposed&#xD;
           participants, 28 days after the last injection.&#xD;
&#xD;
        -  To demonstrate the superiority of the immune response elicited by CYD dengue vaccine&#xD;
           given as a 2-dose schedule (Group 2) compared to the immune response elicited by CYD&#xD;
           dengue vaccine given as a 3-dose schedule (Group 1), in previously dengue exposed&#xD;
           participants, one year after the last injection.&#xD;
&#xD;
        -  To describe the neutralizing antibody levels of each dengue serotype at 28 days&#xD;
           post-injection 3 to the antibody levels immediately before receiving a booster dose, by&#xD;
           baseline dengue serostatus.&#xD;
&#xD;
        -  To describe the neutralizing antibody levels of each dengue serotype at 28 days&#xD;
           post-injection 2 and 28 days post-injection 3 from Group 1 in a primary series schedule&#xD;
           by baseline dengue serostatus.&#xD;
&#xD;
        -  To demonstrate the superiority of the immune response elicited against each dengue&#xD;
           serotype 28 days after administration of a booster dose of CYD dengue vaccine, in&#xD;
           previously dengue exposed participants, at one year or two years after last injection in&#xD;
           the primary series.&#xD;
&#xD;
        -  To describe the seroconversion rate 28 days post-booster injection in all 3 groups.&#xD;
&#xD;
        -  To describe all hospitalized virologically confirmed dengue (VCD) cases during the&#xD;
           study.&#xD;
&#xD;
        -  To evaluate the safety profile of CYD after each and any injection during the trial.&#xD;
           Safety assessments include solicited reactions within 7 or 14 days after each injection,&#xD;
           unsolicited adverse events within 28 days after each injection, and serious adverse&#xD;
           events during the study period.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Healthy participants aged between 9 and 50 year received CYD dengue vaccine in various&#xD;
      schedules, in two sequential stages. In the first stage, participants received 1, 2 or 3&#xD;
      injections of CYD dengue vaccine over a 12-month period. In the second stage, participants&#xD;
      were randomized to receive a booster dose of CYD dengue vaccine at either 12 months (Subgroup&#xD;
      a) or 24 months (Subgroup b) after the third injection of study vaccine. During the&#xD;
      conduction of this trial, the World Health Organization (WHO) indication about vaccinating&#xD;
      only baseline seropositive participants was arisen; at this moment, STAGE I of the trial was&#xD;
      completed. For STAGE II, only participants who were previously dengue exposed at baseline&#xD;
      (dengue seropositive) were eligible to receive the booster dose.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2, 2016</start_date>
  <completion_date type="Actual">April 29, 2020</completion_date>
  <primary_completion_date type="Actual">April 29, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>STAGE-I: Geometric Mean Titers (GMTs) Against Each Dengue Virus Serotype 28 Days After Last CYD Dengue Vaccination in Participants Who Were Seropositive at Baseline</measure>
    <time_frame>28 days after last CYD dengue vaccination</time_frame>
    <description>GMTs of antibodies against each of the 4 dengue virus serotypes (1, 2, 3, or 4) were assessed using plaque reduction neutralization test (PRNT) assay method. Titers were measured in terms of 1/dilution. Dengue seropositive participants at Baseline was defined as participants with titers &gt;=10 (1/dilution) for at least 1 serotype with parental dengue virus strains. Per-protocol analysis set (PPAS) included all participants who had no protocol violations; and who met any of following study violations were excluded from PPAS (STAGE I/II): had not met all protocol-specified inclusion/exclusion criteria, had not received correct doses or injections, received vaccine other than randomized schedule, did not receive vaccination in proper time window, had not provided post-dose serology sample in proper time window, received protocol-restricted medication, therapy, or vaccine.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>STAGE-I: Geometric Mean Titers Against Each Dengue Virus Serotype 1 Year After Last CYD Dengue Vaccination in Participants Who Were Seropositive at Baseline</measure>
    <time_frame>1 year after last CYD dengue vaccination</time_frame>
    <description>GMTs of antibodies against each of the 4 dengue virus serotypes (1, 2, 3 or 4) were assessed using the PRNT assay method. Titers were measured in terms of 1/dilution. Dengue seropositive participants at Baseline were defined as participants with titers &gt;=10 (1/dilution) for at least one serotype with the parental dengue virus strains.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>STAGE-II: Geometric Mean Titers Against Each Dengue Virus Serotype Within Group 1a and Group 1 After the Third Dose of CYD Dengue Vaccination in Participants Who Were Seropositive at Baseline</measure>
    <time_frame>Group 1: 28 days post-dose 3 in STAGE-I, Group 1a: 28 days post 12 months booster dose in STAGE-II</time_frame>
    <description>GMTs of antibodies against each of the 4 dengue virus serotypes (1, 2, 3 or 4) were assessed using the PRNT assay method. Titers were measured in terms of 1/dilution. Dengue seropositive participants at Baseline were defined as participants with titers &gt;=10 (1/dilution) for at least one serotype with the parental dengue virus strains. Data of Group 1 (28 days post-dose 3 in STAGE-I) and Group 1a (28 days 12 months Booster dose) were reported and compared in this outcome measure. GMT paired ratio (given in statistical analysis section) was calculated by dividing geometric mean values of Group 1a: 28 days post 12 months booster dose in STAGE-II by Group 1: 28 days post-dose 3 in STAGE-I.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>STAGE-II: Geometric Mean Titers Against Each Dengue Virus Serotype Comparison Between Group 2a and Group 1 After the Third Dose of CYD Dengue Vaccination in Participants Who Were Seropositive at Baseline</measure>
    <time_frame>Group 1: 28 days post-dose 3 in STAGE-I, Group 2a: 28 days post 12 months booster dose in STAGE-II</time_frame>
    <description>GMTs of antibodies against each of the 4 dengue virus serotypes (1, 2, 3 or 4) were assessed using the PRNT assay method. Titers were measured in terms of 1/dilution. Dengue seropositive participants at Baseline were defined as participants with titers &gt;=10 (1/dilution) for at least one serotype with the parental dengue virus strains. Data of Group 1 (28 days post-dose 3 in STAGE-I) and Group 2a (28 days post 12 months Booster dose) were reported and compared in this outcome measure. GMT ratio (given in statistical analysis section) was calculated by dividing geometric mean values of Group 2a: 28 days post 12 months booster dose in STAGE-II by Group 1: 28 days Post-dose 3 in STAGE-I.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>STAGE-II: Geometric Mean Titers Against Each Dengue Virus Serotype Within Group 1b and Group 1 After the Third Dose of CYD Dengue Vaccination in Participants Who Were Seropositive at Baseline</measure>
    <time_frame>Group 1: 28 days post-dose 3 in STAGE-I, Group 1b: 28 days post 24 months booster dose in STAGE-II</time_frame>
    <description>GMTs of antibodies against each of the 4 dengue virus serotypes (1, 2, 3 or 4) were assessed using the PRNT assay method. Titers were measured in terms of 1/dilution. Dengue seropositive participants at Baseline were defined as participants with titers &gt;=10 (1/dilution) for at least one serotype with the parental dengue virus strains. Data of Group 1 (28 days post-dose 3 in STAGE-I) and Group 1b (28 days post 24 months booster dose) were reported and compared in this outcome measure. GMT paired ratio (given in statistical analysis section) was calculated by dividing geometric mean values of Group 1b: 28 days post 24 months booster dose in STAGE-II by Group 1: 28 days Post-dose 3 in STAGE-I.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>STAGE-II: Geometric Mean Titers Against Each Dengue Virus Serotype Comparison Between Group 2b and Group 1 After the Third Dose of CYD Dengue Vaccination in Participants Who Were Seropositive at Baseline</measure>
    <time_frame>Group 1: 28 days post-dose 3 in STAGE-I, Group 2b: 28 days post 24 months Booster dose in STAGE-II</time_frame>
    <description>GMTs of antibodies against each of the 4 dengue virus serotypes (1, 2, 3 or 4) were assessed using the PRNT assay method. Titers were measured in terms of 1/dilution. Dengue seropositive participants at Baseline were defined as participants with titers &gt;=10 (1/dilution) for at least one serotype with the parental dengue virus strains. Data of Group 1 (28 days post-dose 3 in STAGE-I) and Group 2b (28 days post 24 months Booster dose) was reported and compared in this outcome measure. GMT ratio (given in statistical analysis section) was calculated by dividing geometric mean values of Group 2b: 28 days post 24 months booster dose in STAGE-II by Group 1: 28 days post-dose 3 in STAGE-I.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>STAGE-I: Geometric Mean Titers Against Each Serotype With the Parental Dengue Virus Strains After CYD Dengue Vaccination in Participants Who Were Seropositive at Baseline-Comparison Between Group 1 and Group 2</measure>
    <time_frame>28 days and 1 year after last CYD dengue vaccination</time_frame>
    <description>GMTs of antibodies against each of the 4 dengue virus serotypes (1, 2, 3 or 4) were assessed using the PRNT assay method. Titers were measured in terms of 1/dilution. Dengue seropositive participants at Baseline were defined as participants with titers &gt;=10 (1/dilution) for at least one serotype with the parental dengue virus strains.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>STAGE-I: Geometric Mean Titers Against Each Serotype With the Parental Dengue Virus Strains in All Participants</measure>
    <time_frame>Baseline, 28 days post vaccination 3, and 1 year post vaccination 3</time_frame>
    <description>GMTs of antibodies against each of the 4 dengue virus serotypes (parental strains) were assessed using the PRNT assay method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>STAGE-I: Geometric Mean Titers Against Each Serotype With the Parental Dengue Virus Strains (by Baseline Dengue Status) in Participants Who Were Seropositive and Seronegative at Baseline</measure>
    <time_frame>Baseline, 28 days post vaccination 3, and 1 year post vaccination 3</time_frame>
    <description>GMTs of antibodies against each of the 4 dengue virus serotypes (1, 2, 3, or 4) were assessed using the PRNT assay method. Titers were measured in terms of 1/dilution. Dengue seropositive participants at Baseline were defined as participants with titers &gt;=10 (1/dilution) for at least one serotype with the parental dengue virus strains. Dengue seronegative participants at Baseline were defined as the participants with valid titer &lt;0 (1/dilution) for all serotypes with parental dengue virus strains.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>STAGE-II: Geometric Mean Titers Against Each Serotype With the Parental Dengue Virus Strains After Booster CYD Dengue Vaccination in Participants Seropositive at Baseline</measure>
    <time_frame>Baseline, 28 days post vaccination-3, and 28 days post booster dose</time_frame>
    <description>GMTs of antibodies against each of the 4 dengue virus serotype (1, 2, 3, or 4) were assessed using the PRNT assay. Dengue seropositive participants at Baseline were defined as participants with titers &gt;=10 (1/dilution) for at least one serotype with the parental dengue virus strains. Titers were measured in terms of 1/dilution.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>STAGE-I: Percentage of Participants With Antibodies Titer &gt;=10 (1/Dilution) Against Each Serotype With the Parental Dengue Virus Strains in All Participants</measure>
    <time_frame>Baseline, 28 days post vaccination 3, and 1 year post vaccination 3</time_frame>
    <description>GMTs of antibodies against each of the 4 dengue virus serotypes (1, 2, 3 or 4) were assessed using the PRNT assay.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>STAGE-II: Percentage of Participants With Antibodies Titer &gt;=10 (1/Dilution) Against Each Serotype With the Parental Dengue Virus Strain in Participants Seropositive at Baseline</measure>
    <time_frame>Baseline, 28 days post vaccination 3, and 1 year post vaccination 3</time_frame>
    <description>GMTs of antibodies against each of the 4 dengue virus serotypes (1, 2, 3 or 4) were assessed using the PRNT assay method. Dengue seropositive participants at Baseline were defined as participants with titers &gt;=10 (1/dilution) for at least one serotype with the parental dengue virus strains.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>STAGE-I: Number of Participants With Immediate Unsolicited Adverse Events Following Vaccination With CYD Dengue Vaccine or Placebo (Post Any Vaccination)</measure>
    <time_frame>Within 30 minutes after any vaccination (1, 2, or 3)</time_frame>
    <description>An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the electronic case report form (eCRF) in terms of diagnosis and/or onset post-vaccination. Immediate unsolicited AE were AEs that occurred within 30 minutes after any vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>STAGE-II: Number of Participants With Immediate Unsolicited Adverse Events Following Booster Vaccination With CYD Dengue Vaccine</measure>
    <time_frame>Within 30 minutes after CYD booster vaccination</time_frame>
    <description>An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the eCRF in terms of diagnosis and / or onset post-vaccination. Immediate unsolicited AE were AEs that occurred within 30 minutes after vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>STAGE-I: Number of Participants With Solicited Injection Site Reactions Following Vaccination With CYD Dengue Vaccine or Placebo (Post Any Vaccination)</measure>
    <time_frame>Within 7 days after any vaccination (1, 2, or 3)</time_frame>
    <description>Adverse reaction (AR) was defined as all noxious and unintended responses to a medicinal product related to any dose. A Solicited Reaction (SR) was defined as an AR observed and reported under the conditions (symptom and onset) prelisted (i.e., solicited) in the eCRF and considered as related to vaccination. Solicited injection site reaction was an AR at and around the injection site that included pain, erythema, and swelling.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>STAGE-I: Number of Participants With Solicited Injection Site Reactions Following Vaccination With CYD Dengue Vaccine or Placebo (Post Each Vaccination)</measure>
    <time_frame>Within 7 days after each vaccination (1, 2, and 3)</time_frame>
    <description>AR was defined as all noxious and unintended responses to a medicinal product related to any dose. An SR was defined as an AR observed and reported under the conditions (symptom and onset) prelisted (i.e., solicited) in the eCRF and considered as related to vaccination. Solicited injection site reaction was an AR at and around the injection site that included pain, erythema, and swelling.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>STAGE-I: Number of Participants With Solicited Systemic Reactions Following Vaccination With CYD Dengue Vaccine or Placebo (Post Any Vaccination)</measure>
    <time_frame>Within 14 days after any vaccination (1, 2, or 3)</time_frame>
    <description>An AR was defined as all noxious and unintended responses to a medicinal product related to any dose. An SR was defined as an AR observed and reported under the conditions (symptom and onset) prelisted (i.e., solicited) in the eCRF and considered as related to vaccination. Systemic AEs were all AEs that were not injection site reactions. Solicited systemic reactions included fever, headache, malaise, myalgia, and asthenia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>STAGE-I: Number of Participants With Solicited Systemic Reactions Following Vaccination With CYD Dengue Vaccine or Placebo (Post Each Vaccination)</measure>
    <time_frame>Within 14 days after each vaccination (1, 2, and 3)</time_frame>
    <description>An AR was defined as all noxious and unintended responses to a medicinal product related to any dose. A SR was defined as an AR observed and reported under the conditions (symptom and onset) prelisted (i.e., solicited) in the eCRF and considered as related to vaccination. Solicited systemic reactions included fever, headache, malaise, myalgia, and asthenia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>STAGE-II: Number of Participants With Solicited Injection Site Reactions Following Booster Vaccination With CYD Dengue Vaccine</measure>
    <time_frame>Within 7 days after CYD booster vaccination</time_frame>
    <description>An AR was defined as all noxious and unintended responses to a medicinal product related to any dose. A SR was defined as an AR observed and reported under the conditions (symptom and onset) prelisted (i.e., solicited) in the eCRF and considered as related to vaccination. Solicited injection site reaction was an AR at and around the injection site that included pain, erythema, and swelling.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>STAGE-II: Number of Participants With Solicited Systemic Reactions Following Booster Vaccination With CYD Dengue Vaccine</measure>
    <time_frame>Within 14 days after CYD booster vaccination</time_frame>
    <description>An AR was defined as all noxious and unintended responses to a medicinal product related to any dose. A SR was defined as an AR observed and reported under the conditions (symptom and onset) prelisted (i.e., solicited) in the eCRF and considered as related to vaccination. Solicited systemic reactions included fever, headache, malaise, myalgia, and asthenia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>STAGE-I: Number of Participants Reporting Unsolicited Adverse Events Following Vaccination With CYD Dengue Vaccine or Placebo</measure>
    <time_frame>Within 28 days after any vaccination (1, 2, or 3)</time_frame>
    <description>An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the eCRF in terms of diagnosis and/or onset post-vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>STAGE-II: Number of Participants Reporting Unsolicited Adverse Events Following Booster Vaccination With CYD Dengue Vaccine</measure>
    <time_frame>Within 28 days after CYD booster Vaccination</time_frame>
    <description>An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An unsolicited AE was an observed AE that does not fulfill the conditions prelisted in the eCRF in terms of diagnosis and/or onset post-vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>STAGE-I: Number of Participants Reporting Serious Adverse Events Including Serious Adverse Event of Special Interests (AESI) Following Vaccination With CYD Dengue Vaccine or Placebo</measure>
    <time_frame>From Day 0 (post vaccination) up to 12 months after last vaccination in STAGE-I (i.e., up to 24 months)</time_frame>
    <description>An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE was any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was congenital anomaly/birth defect, or was an important medical event. AESI were AEs that were considered by the Sponsor to be relevant for the monitoring of the safety profile of the investigational vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>STAGE-II: Number of Participants Reporting Serious Adverse Events Including Serious Adverse Events Special Interest Following Booster Vaccination With CYD Dengue Vaccine</measure>
    <time_frame>From Month 25 up to 6 months after CYD booster injection (either at 1 year or 2 year) (i.e., up to 30 months for Groups 1a, 2a, and 3a and up to 42 months for Groups 1b, 2b, and 3b)</time_frame>
    <description>An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE was any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was congenital anomaly/birth defect, or was an important medical event. AESI were AEs that were considered by the Sponsor to be relevant for the monitoring of the safety profile of the investigational vaccine.</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">1050</enrollment>
  <condition>Dengue Fever</condition>
  <condition>Dengue Hemorrhagic Fever</condition>
  <arm_group>
    <arm_group_label>STAGE-I Group 1: CYD Dengue Vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 3 doses of CYD dengue vaccine 0.5 milliliters (mL) subcutaneously (SC) at Day 0 (Vaccination 1), Month 6 (Vaccination 2), and Month 12 (Vaccination 3).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>STAGE-I Group 2: Placebo + CYD Dengue Vaccine (Months 6,12)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received a dose of placebo at Day 0 (Vaccination 1) along with 2 doses of CYD dengue vaccine 0.5 mL SC at Month 6 (Vaccination 2) and Month 12 (Vaccination 3).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>STAGE-I Group 3: Placebo + CYD Dengue Vaccine (Month 12)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received 2 doses of placebo at Day 0 (Vaccination 1) and Month 6 (Vaccination 2) along with a dose of CYD dengue vaccine 0.5 mL SC at Month 12 (Vaccination 3).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>STAGE-II Group 1a: CYD Vaccine + CYD Booster Vaccine (1 Year)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants from Group 1 who received vaccination in STAGE-I; and were seropositive at Baseline received a booster dose of CYD dengue vaccine in STAGE-II at 1 year post last dose in STAGE-I (i.e., at Month 24).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>STAGE-II Group 2a: Placebo + CYD + CYD Booster (1 Year)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants from Group 2 who received vaccination in STAGE-I and were seropositive at baseline received a booster injection of CYD dengue vaccine in STAGE-II at 1 year post last dose in STAGE-I (i.e., at Month 24).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>STAGE-II Group 3a: Placebo + CYD + CYD Booster (1 Year)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants from Group 3 who received vaccination in STAGE-I and were seropositive at Baseline received a booster injection of CYD dengue vaccine in STAGE-II at 1 year post last dose in STAGE-I (i.e., at Month 24).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>STAGE-II Group 1b: CYD Vaccine + CYD Booster Vaccine (2 Years)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants from Group 1 who received vaccination in STAGE-I and were seropositive at Baseline received a booster injection of CYD dengue vaccine in STAGE-II at 2 years post last dose in STAGE-I (i.e., at Month 36).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>STAGE-II Group 2b: Placebo + CYD + CYD Booster (2 Years)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants from Group 2 who received vaccination in STAGE-I and were seropositive at Baseline received a booster injection of CYD dengue vaccine in STAGE-II at 2 years post last dose in STAGE-I (i.e., at Month 36).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>STAGE-II Group 3b: Placebo + CYD + CYD Booster (2 Years)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants from Group 3 who received vaccination in STAGE-I and were seropositive at baseline received a booster injection of CYD dengue vaccine in STAGE-II at 2 years post last dose in STAGE-I (i.e., at Month 36).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CYD Dengue Vaccine</intervention_name>
    <description>0.5 mL, Subcutaneous</description>
    <arm_group_label>STAGE-I Group 1: CYD Dengue Vaccine</arm_group_label>
    <arm_group_label>STAGE-I Group 2: Placebo + CYD Dengue Vaccine (Months 6,12)</arm_group_label>
    <arm_group_label>STAGE-I Group 3: Placebo + CYD Dengue Vaccine (Month 12)</arm_group_label>
    <arm_group_label>STAGE-II Group 1a: CYD Vaccine + CYD Booster Vaccine (1 Year)</arm_group_label>
    <arm_group_label>STAGE-II Group 1b: CYD Vaccine + CYD Booster Vaccine (2 Years)</arm_group_label>
    <arm_group_label>STAGE-II Group 2a: Placebo + CYD + CYD Booster (1 Year)</arm_group_label>
    <arm_group_label>STAGE-II Group 2b: Placebo + CYD + CYD Booster (2 Years)</arm_group_label>
    <arm_group_label>STAGE-II Group 3a: Placebo + CYD + CYD Booster (1 Year)</arm_group_label>
    <arm_group_label>STAGE-II Group 3b: Placebo + CYD + CYD Booster (2 Years)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo (Sodium chloride 0.9%)</intervention_name>
    <description>0.5 mL, Subcutaneous</description>
    <arm_group_label>STAGE-I Group 2: Placebo + CYD Dengue Vaccine (Months 6,12)</arm_group_label>
    <arm_group_label>STAGE-I Group 3: Placebo + CYD Dengue Vaccine (Month 12)</arm_group_label>
    <arm_group_label>STAGE-II Group 2a: Placebo + CYD + CYD Booster (1 Year)</arm_group_label>
    <arm_group_label>STAGE-II Group 2b: Placebo + CYD + CYD Booster (2 Years)</arm_group_label>
    <arm_group_label>STAGE-II Group 3a: Placebo + CYD + CYD Booster (1 Year)</arm_group_label>
    <arm_group_label>STAGE-II Group 3b: Placebo + CYD + CYD Booster (2 Years)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 9 to 50 years on the day of enrollment.&#xD;
&#xD;
          -  Participant in good health, based on medical history and physical examination.&#xD;
&#xD;
          -  Assent form or informed consent form (ICF) had been signed and dated by the&#xD;
             participant (based on local regulations), and ICF had been signed and dated by the&#xD;
             parent(s) or another legally acceptable representative (and by an independent witness&#xD;
             if required by local regulations).&#xD;
&#xD;
          -  Participant and parent(s)/legally acceptable representative(s) were able to attend all&#xD;
             scheduled visits and to comply with all trial procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participant was pregnant, or lactating, or of childbearing potential (to be considered&#xD;
             of non-childbearing potential, a female must be pre-menarche, surgically sterile, or&#xD;
             using an effective method of contraception or abstinence from at least 4 weeks prior&#xD;
             to the first vaccination until at least 4 weeks after the last vaccination).&#xD;
&#xD;
          -  Participation at the time of study enrollment (or in the 4 weeks preceding the first&#xD;
             trial vaccination) or planned participation during the present trial period in another&#xD;
             clinical trial investigating a vaccine, drug, medical device or medical procedure.&#xD;
&#xD;
          -  Self-reported or suspected congenital or acquired immunodeficiency; or receipt of&#xD;
             immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within&#xD;
             the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or&#xD;
             equivalent for more than 2 consecutive weeks within the past 3 months).&#xD;
&#xD;
          -  Self-reported systemic hypersensitivity to any of the vaccine components, or history&#xD;
             of a life-threatening reaction to the vaccine used in the trial or to a vaccine&#xD;
             containing any of the same substances.&#xD;
&#xD;
          -  Chronic illness that, in the opinion of the investigator, was at a stage where it&#xD;
             might interfere with trial conduct or completion.&#xD;
&#xD;
          -  Receipt of blood or blood-derived products in the past 3 months, which might interfere&#xD;
             with assessment of the immune response.&#xD;
&#xD;
          -  Planned receipt of any vaccine in the 4 weeks following any trial vaccination.&#xD;
&#xD;
          -  Previous vaccination against dengue disease with either the trial vaccine or another&#xD;
             vaccine.&#xD;
&#xD;
          -  Deprived of freedom by an administrative or court order, or in an emergency setting,&#xD;
             or hospitalized involuntarily.&#xD;
&#xD;
          -  Current alcohol abuse or drug addiction that, based on investigator's judgment, might&#xD;
             interfere with the participant's ability to comply with trial procedures.&#xD;
&#xD;
          -  Identified as a site employee of the Investigator, with direct involvement in the&#xD;
             proposed study or other studies under the direction of that Investigator or study&#xD;
             center, as well as family members (i.e., immediate, husband, wife, and their children,&#xD;
             adopted or natural) of the employees or the Investigator.&#xD;
&#xD;
          -  A prospective participant must not be included in the study until the following&#xD;
             conditions and/or symptoms were resolved:&#xD;
&#xD;
               -  Febrile illness (temperature greater than or equal to [&gt;=] 38.0 degree Celsius)&#xD;
                  or moderate or severe acute illness/infection (according to Investigator's&#xD;
                  judgment) on the day of vaccination.&#xD;
&#xD;
               -  Receipt of any vaccine in the 4 weeks preceding the first trial vaccination.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur, a Sanofi Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site 102</name>
      <address>
        <city>Barranquilla</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 101</name>
      <address>
        <city>Cali</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 103</name>
      <address>
        <city>Medellin</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 203</name>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site 204</name>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Primary Site Muntinlupa 201_Satellite Site San Pablo 202</name>
      <address>
        <city>Muntinlupa</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Colombia</country>
    <country>Philippines</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>December 9, 2015</study_first_submitted>
  <study_first_submitted_qc>December 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2015</study_first_posted>
  <results_first_submitted>December 11, 2020</results_first_submitted>
  <results_first_submitted_qc>February 3, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 23, 2021</results_first_posted>
  <last_update_submitted>February 3, 2021</last_update_submitted>
  <last_update_submitted_qc>February 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dengue Fever</keyword>
  <keyword>Dengue virus</keyword>
  <keyword>Dengue Hemorrhagic Fever</keyword>
  <keyword>CYD Dengue Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dengue</mesh_term>
    <mesh_term>Hemorrhagic Fevers, Viral</mesh_term>
    <mesh_term>Severe Dengue</mesh_term>
    <mesh_term>Fever</mesh_term>
    <mesh_term>Hyperthermia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 12, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/44/NCT02628444/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 19, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/44/NCT02628444/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 6 active centers in 2 countries. A total of 1050 participants were enrolled from 02 May 2016 to 16 September 2016.</recruitment_details>
      <pre_assignment_details>Participants were enrolled and randomized in 1:1:1 ratio to 1 of 3 treatment arms in STAGE-I. After STAGE-I, participants identified as seropositive at Baseline were randomized in ratio 1:1 to 1 of 2 subgroups (a [1a, 2a, 3a] or b [1b, 2b, 3b]) and received one CYD booster vaccine in STAGE-II at either 12 months (Subgroup a) or 24 months (Subgroup b) post last vaccination in STAGE-I. Here, 'M' in the period titles signifies months.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>STAGE-I Group 1: CYD Dengue Vaccine</title>
          <description>Participants received 3 doses of CYD dengue vaccine 0.5 milliliters (mL) subcutaneously (SC) at Day 0 (Vaccination 1), Month 6 (Vaccination 2), and Month 12 (Vaccination 3).</description>
        </group>
        <group group_id="P2">
          <title>STAGE-I Group 2: Placebo + CYD Dengue Vaccine (Months 6,12)</title>
          <description>Participants received a dose of placebo at Day 0 (Vaccination 1) along with 2 doses of CYD dengue vaccine 0.5 mL SC at Month 6 (Vaccination 2) and Month 12 (Vaccination 3).</description>
        </group>
        <group group_id="P3">
          <title>STAGE-I Group 3: Placebo + CYD Dengue Vaccine (Month 12)</title>
          <description>Participants received 2 doses of placebo at Day 0 (Vaccination 1) and Month 6 (Vaccination 2) along with a dose of CYD dengue vaccine 0.5 mL SC at Month 12 (Vaccination 3).</description>
        </group>
        <group group_id="P4">
          <title>STAGE-II Group 1a: CYD Vaccine + CYD Booster Vaccine (1 Year)</title>
          <description>Participants from Group 1 who received vaccination in STAGE-I and were seropositive at Baseline received a booster dose of CYD dengue vaccine in STAGE-II at 1 year post last dose in STAGE-I (i.e., at Month 24).</description>
        </group>
        <group group_id="P5">
          <title>STAGE-II Group 2a: Placebo + CYD + CYD Booster (1 Year)</title>
          <description>Participants from Group 2 who received vaccination in STAGE-I and were seropositive at baseline received a booster injection of CYD dengue vaccine in STAGE-II at 1 year post last dose in STAGE-I (i.e., at Month 24).</description>
        </group>
        <group group_id="P6">
          <title>STAGE-II Group 3a: Placebo + CYD + CYD Booster (1 Year)</title>
          <description>Participants from Group 3 who received vaccination in STAGE-I and were seropositive at Baseline received a booster injection of CYD dengue vaccine in STAGE-II at 1 year post last dose in STAGE-I (i.e., at Month 24).</description>
        </group>
        <group group_id="P7">
          <title>STAGE-II Group 1b: CYD Vaccine + CYD Booster Vaccine (2 Years)</title>
          <description>Participants from Group 1 who received vaccination in STAGE-I and were seropositive at Baseline received a booster injection of CYD dengue vaccine in STAGE-II at 2 years post last dose in STAGE-I (i.e., at Month 36).</description>
        </group>
        <group group_id="P8">
          <title>STAGE-II Group 2b: Placebo + CYD + CYD Booster (2 Years)</title>
          <description>Participants from Group 2 who received vaccination in STAGE-I and were seropositive at Baseline received a booster injection of CYD dengue vaccine in STAGE-II at 2 years post last dose in STAGE-I (i.e., at Month 36).</description>
        </group>
        <group group_id="P9">
          <title>STAGE-II Group 3b: Placebo + CYD + CYD Booster (2 Years)</title>
          <description>Participants from Group 3 who received vaccination in STAGE-I and were seropositive at baseline received a booster injection of CYD dengue vaccine in STAGE-II at 2 years post last dose in STAGE-I (i.e., at Month 36).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Stage-I(24M:12M Treatment+12M Follow-up)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="350"/>
                <participants group_id="P2" count="348"/>
                <participants group_id="P3" count="352"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated</title>
              <participants_list>
                <participants group_id="P1" count="348"/>
                <participants group_id="P2" count="348"/>
                <participants group_id="P3" count="352"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Full Analysis Set (FAS)</title>
              <participants_list>
                <participants group_id="P1" count="333"/>
                <participants group_id="P2" count="328"/>
                <participants group_id="P3" count="332"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="314"/>
                <participants group_id="P2" count="309"/>
                <participants group_id="P3" count="310"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="39"/>
                <participants group_id="P3" count="42"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse event (AE) intensity less than (&lt;) Grade 1</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Serious AE (SAE)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Voluntary withdrawal not due to AE</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with protocol</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>STAGE-II(18M:12M Treatment+6M Follow-up)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="145"/>
                <participants group_id="P5" count="152"/>
                <participants group_id="P6" count="157"/>
                <participants group_id="P7" count="149"/>
                <participants group_id="P8" count="152"/>
                <participants group_id="P9" count="151"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="55"/>
                <participants group_id="P5" count="59"/>
                <participants group_id="P6" count="62"/>
                <participants group_id="P7" count="53"/>
                <participants group_id="P8" count="56"/>
                <participants group_id="P9" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="55"/>
                <participants group_id="P5" count="59"/>
                <participants group_id="P6" count="62"/>
                <participants group_id="P7" count="53"/>
                <participants group_id="P8" count="54"/>
                <participants group_id="P9" count="52"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="90"/>
                <participants group_id="P5" count="93"/>
                <participants group_id="P6" count="95"/>
                <participants group_id="P7" count="96"/>
                <participants group_id="P8" count="98"/>
                <participants group_id="P9" count="99"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Other AE</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with protocol</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="83"/>
                <participants group_id="P5" count="83"/>
                <participants group_id="P6" count="83"/>
                <participants group_id="P7" count="81"/>
                <participants group_id="P8" count="84"/>
                <participants group_id="P9" count="85"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Voluntary withdrawal not due to AE</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="10"/>
                <participants group_id="P7" count="12"/>
                <participants group_id="P8" count="11"/>
                <participants group_id="P9" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>SAE</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Analysis was performed on all randomized population.</population>
      <group_list>
        <group group_id="B1">
          <title>STAGE-I Group 1: CYD Dengue Vaccine</title>
          <description>Participants received 3 doses of CYD dengue vaccine 0.5 mL SC at Day 0 (Vaccination 1), Month 6 (Vaccination 2), and Month 12 (Vaccination 3).</description>
        </group>
        <group group_id="B2">
          <title>STAGE-I Group 2: Placebo + CYD Dengue Vaccine (Months 6,12)</title>
          <description>Participants received a dose of placebo at Day 0 (Vaccination 1) along with 2 doses of CYD dengue vaccine 0.5 mL SC at Month 6 (Vaccination 2) and Month 12 (Vaccination 3).</description>
        </group>
        <group group_id="B3">
          <title>STAGE-I Group 3: Placebo + CYD Dengue Vaccine (Month 12)</title>
          <description>Participants received 2 doses of placebo at Day 0 (Vaccination 1) and Month 6 (Vaccination 2) along with a dose of CYD dengue vaccine 0.5 mL SC at Month 12 (Vaccination 3).</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="350"/>
            <count group_id="B2" value="348"/>
            <count group_id="B3" value="352"/>
            <count group_id="B4" value="1050"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.8" spread="14.42"/>
                    <measurement group_id="B2" value="31.3" spread="14.47"/>
                    <measurement group_id="B3" value="31.1" spread="14.62"/>
                    <measurement group_id="B4" value="31.1" spread="14.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="190"/>
                    <measurement group_id="B2" value="197"/>
                    <measurement group_id="B3" value="185"/>
                    <measurement group_id="B4" value="572"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="160"/>
                    <measurement group_id="B2" value="151"/>
                    <measurement group_id="B3" value="167"/>
                    <measurement group_id="B4" value="478"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="171"/>
                    <measurement group_id="B2" value="172"/>
                    <measurement group_id="B3" value="169"/>
                    <measurement group_id="B4" value="512"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="174"/>
                    <measurement group_id="B2" value="172"/>
                    <measurement group_id="B3" value="177"/>
                    <measurement group_id="B4" value="523"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Dengue Baseline Status</title>
          <description>Baseline dengue seropositive participants: participants with greater than equal to (&gt;=) 10 (1/dilution) for at least 1 serotype with parental dengue virus strain. Baseline dengue seronegative participants were defined as participants with valid titer less than (&lt;) 10 (1/dilution) for all serotypes with parental dengue virus strains. Baseline dengue status was evaluated in FAS population that included participants who had received either at least 1 injection of either CYD dengue vaccine or placebo and had at least 1 blood sample drawn and valid post-injection serology results.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Seropositive participants</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="281"/>
                    <measurement group_id="B2" value="288"/>
                    <measurement group_id="B3" value="291"/>
                    <measurement group_id="B4" value="860"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seronegative participants</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="41"/>
                    <measurement group_id="B4" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Undetermined</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>STAGE-I: Geometric Mean Titers (GMTs) Against Each Dengue Virus Serotype 28 Days After Last CYD Dengue Vaccination in Participants Who Were Seropositive at Baseline</title>
        <description>GMTs of antibodies against each of the 4 dengue virus serotypes (1, 2, 3, or 4) were assessed using plaque reduction neutralization test (PRNT) assay method. Titers were measured in terms of 1/dilution. Dengue seropositive participants at Baseline was defined as participants with titers &gt;=10 (1/dilution) for at least 1 serotype with parental dengue virus strains. Per-protocol analysis set (PPAS) included all participants who had no protocol violations; and who met any of following study violations were excluded from PPAS (STAGE I/II): had not met all protocol-specified inclusion/exclusion criteria, had not received correct doses or injections, received vaccine other than randomized schedule, did not receive vaccination in proper time window, had not provided post-dose serology sample in proper time window, received protocol-restricted medication, therapy, or vaccine.</description>
        <time_frame>28 days after last CYD dengue vaccination</time_frame>
        <population>Analysis performed on PPAS. Here, 'Overall number of participant analyzed'=participants with available data for this outcome measure. Data for this outcome measure was not planned to be collected and analyzed for Group 3, as pre-specified in protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>STAGE-I Group 1: CYD Dengue Vaccine</title>
            <description>Participants received 3 doses of CYD dengue vaccine 0.5 mL SC at Day 0 (Vaccination 1), Month 6 (Vaccination 2), and Month 12 (Vaccination 3).</description>
          </group>
          <group group_id="O2">
            <title>STAGE-I Group 2: Placebo + CYD Dengue Vaccine (Months 6,12)</title>
            <description>Participants received a dose of placebo at Day 0 (Vaccination 1) along with 2 doses of CYD dengue vaccine 0.5 mL SC at Month 6 (Vaccination 2) and Month 12 (Vaccination 3).</description>
          </group>
        </group_list>
        <measure>
          <title>STAGE-I: Geometric Mean Titers (GMTs) Against Each Dengue Virus Serotype 28 Days After Last CYD Dengue Vaccination in Participants Who Were Seropositive at Baseline</title>
          <description>GMTs of antibodies against each of the 4 dengue virus serotypes (1, 2, 3, or 4) were assessed using plaque reduction neutralization test (PRNT) assay method. Titers were measured in terms of 1/dilution. Dengue seropositive participants at Baseline was defined as participants with titers &gt;=10 (1/dilution) for at least 1 serotype with parental dengue virus strains. Per-protocol analysis set (PPAS) included all participants who had no protocol violations; and who met any of following study violations were excluded from PPAS (STAGE I/II): had not met all protocol-specified inclusion/exclusion criteria, had not received correct doses or injections, received vaccine other than randomized schedule, did not receive vaccination in proper time window, had not provided post-dose serology sample in proper time window, received protocol-restricted medication, therapy, or vaccine.</description>
          <population>Analysis performed on PPAS. Here, 'Overall number of participant analyzed'=participants with available data for this outcome measure. Data for this outcome measure was not planned to be collected and analyzed for Group 3, as pre-specified in protocol.</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="265"/>
                <count group_id="O2" value="272"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="822" lower_limit="700" upper_limit="964"/>
                    <measurement group_id="O2" value="899" lower_limit="752" upper_limit="1075"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="875" lower_limit="770" upper_limit="995"/>
                    <measurement group_id="O2" value="869" lower_limit="754" upper_limit="1002"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="610" lower_limit="535" upper_limit="694"/>
                    <measurement group_id="O2" value="599" lower_limit="524" upper_limit="685"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="531" lower_limit="470" upper_limit="601"/>
                    <measurement group_id="O2" value="510" lower_limit="453" upper_limit="575"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Group 2/Group 1: Serotype 1</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority was demonstrated if the lower limit of the two-sided 95% confidence interval (CI) of the ratio of GMTs between groups (Group 2/Group 1) was greater than (&gt;) 1/2. Overall non-inferiority was demonstrated if all 4 serotypes achieved non-inferiority.</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>1.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.862</ci_lower_limit>
            <ci_upper_limit>1.39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Group 2/Group 1: Serotype 2</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority was demonstrated if the lower limit of the two-sided 95% CI of the ratio of GMTs between groups (Group 2/Group 1) was &gt;1/2. Overall non-inferiority was demonstrated if all 4 serotypes achieved non-inferiority.</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.993</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.820</ci_lower_limit>
            <ci_upper_limit>1.20</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Group 2/Group 1: Serotype 3</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority was demonstrated if the lower limit of the two-sided 95% CI of the ratio of GMTs between groups (Group 2/Group 1) was &gt;1/2. Overall non-inferiority was demonstrated if all 4 serotypes achieved non-inferiority.</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.983</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.816</ci_lower_limit>
            <ci_upper_limit>1.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Group 2/Group 1: Serotype 4</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority was demonstrated if the lower limit of the two-sided 95% CI of the ratio of GMTs between groups (Group 2/Group 1) was &gt;1/2. Overall non-inferiority was demonstrated if all 4 serotypes achieved non-inferiority.</non_inferiority_desc>
            <param_type>GMT ratio</param_type>
            <param_value>0.960</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.809</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>STAGE-I: Geometric Mean Titers Against Each Dengue Virus Serotype 1 Year After Last CYD Dengue Vaccination in Participants Who Were Seropositive at Baseline</title>
        <description>GMTs of antibodies against each of the 4 dengue virus serotypes (1, 2, 3 or 4) were assessed using the PRNT assay method. Titers were measured in terms of 1/dilution. Dengue seropositive participants at Baseline were defined as participants with titers &gt;=10 (1/dilution) for at least one serotype with the parental dengue virus strains.</description>
        <time_frame>1 year after last CYD dengue vaccination</time_frame>
        <population>Analysis was performed on PPAS. Here, 'Overall number of participant analyzed'=participants with available data for this outcome measure. Data for this outcome measure was not planned to be collected and analyzed for Group 3, as pre-specified in protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>STAGE-I Group 1: CYD Dengue Vaccine</title>
            <description>Participants received 3 doses of CYD dengue vaccine 0.5 mL SC at Day 0 (Vaccination 1), Month 6 (Vaccination 2), and Month 12 (Vaccination 3).</description>
          </group>
          <group group_id="O2">
            <title>STAGE-I Group 2: Placebo + CYD Dengue Vaccine (Months 6,12)</title>
            <description>Participants received a dose of placebo at Day 0 (Vaccination 1) along with 2 doses of CYD dengue vaccine 0.5 mL SC at Month 6 (Vaccination 2) and Month 12 (Vaccination 3).</description>
          </group>
        </group_list>
        <measure>
          <title>STAGE-I: Geometric Mean Titers Against Each Dengue Virus Serotype 1 Year After Last CYD Dengue Vaccination in Participants Who Were Seropositive at Baseline</title>
          <description>GMTs of antibodies against each of the 4 dengue virus serotypes (1, 2, 3 or 4) were assessed using the PRNT assay method. Titers were measured in terms of 1/dilution. Dengue seropositive participants at Baseline were defined as participants with titers &gt;=10 (1/dilution) for at least one serotype with the parental dengue virus strains.</description>
          <population>Analysis was performed on PPAS. Here, 'Overall number of participant analyzed'=participants with available data for this outcome measure. Data for this outcome measure was not planned to be collected and analyzed for Group 3, as pre-specified in protocol.</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="185"/>
                <count group_id="O2" value="190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="490" lower_limit="398" upper_limit="604"/>
                    <measurement group_id="O2" value="504" lower_limit="403" upper_limit="630"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="821" lower_limit="704" upper_limit="957"/>
                    <measurement group_id="O2" value="737" lower_limit="611" upper_limit="888"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="477" lower_limit="405" upper_limit="561"/>
                    <measurement group_id="O2" value="437" lower_limit="368" upper_limit="519"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="270" lower_limit="235" upper_limit="310"/>
                    <measurement group_id="O2" value="238" lower_limit="205" upper_limit="277"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Group 2/Group 1: Serotype 1</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority was demonstrated if the lower limit of the two-sided 95% CI of the ratio of GMTs between groups (Group 2/Group 1) was &gt;1/2. Overall non-inferiority was demonstrated if all 4 serotypes achieved non-inferiority.</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.757</ci_lower_limit>
            <ci_upper_limit>1.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Group 2/Group 1: Serotype 2</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority was demonstrated if the lower limit of the two-sided 95% CI of the ratio of GMTs between groups (Group 2/Group 1) was &gt;1/2. Overall non-inferiority was demonstrated if all 4 serotypes achieved non-inferiority.</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.897</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.705</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Group 2/Group 1: Serotype 3</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority was demonstrated if the lower limit of the two-sided 95% CI of the ratio of GMTs between groups (Group 2/Group 1) was &gt;1/2. Overall non-inferiority was demonstrated if all 4 serotypes achieved non-inferiority.</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.917</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.724</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Group 2/Group 1: Serotype 4</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority was demonstrated if the lower limit of the two-sided 95% CI of the ratio of GMTs between groups (Group 2/Group 1) was &gt;1/2. Overall non-inferiority was demonstrated if all 4 serotypes achieved non-inferiority.</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.884</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.720</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>STAGE-II: Geometric Mean Titers Against Each Dengue Virus Serotype Within Group 1a and Group 1 After the Third Dose of CYD Dengue Vaccination in Participants Who Were Seropositive at Baseline</title>
        <description>GMTs of antibodies against each of the 4 dengue virus serotypes (1, 2, 3 or 4) were assessed using the PRNT assay method. Titers were measured in terms of 1/dilution. Dengue seropositive participants at Baseline were defined as participants with titers &gt;=10 (1/dilution) for at least one serotype with the parental dengue virus strains. Data of Group 1 (28 days post-dose 3 in STAGE-I) and Group 1a (28 days 12 months Booster dose) were reported and compared in this outcome measure. GMT paired ratio (given in statistical analysis section) was calculated by dividing geometric mean values of Group 1a: 28 days post 12 months booster dose in STAGE-II by Group 1: 28 days post-dose 3 in STAGE-I.</description>
        <time_frame>Group 1: 28 days post-dose 3 in STAGE-I, Group 1a: 28 days post 12 months booster dose in STAGE-II</time_frame>
        <population>Analysis was performed on PPAS. Here, 'Overall number of participant analyzed'=participants with available data for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: CYD Dengue Vaccine-28 Days Post-dose 3 in STAGE-I</title>
            <description>Participants who received 3 doses of CYD dengue vaccine in STAGE-I, and were seropositive at Baseline were assessed 28 days after third CYD vaccine in STAGE-I.</description>
          </group>
          <group group_id="O2">
            <title>Group 1a: CYD Dengue Vaccine-28 Days Post 12 Month Booster Dose</title>
            <description>Participants from Group 1 (STAGE-I) who were seropositive at Baseline and received a booster dose at 1 year (or 12 months) post last dose in STAGE-I, were assessed 28 days after CYD dengue booster dose vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>STAGE-II: Geometric Mean Titers Against Each Dengue Virus Serotype Within Group 1a and Group 1 After the Third Dose of CYD Dengue Vaccination in Participants Who Were Seropositive at Baseline</title>
          <description>GMTs of antibodies against each of the 4 dengue virus serotypes (1, 2, 3 or 4) were assessed using the PRNT assay method. Titers were measured in terms of 1/dilution. Dengue seropositive participants at Baseline were defined as participants with titers &gt;=10 (1/dilution) for at least one serotype with the parental dengue virus strains. Data of Group 1 (28 days post-dose 3 in STAGE-I) and Group 1a (28 days 12 months Booster dose) were reported and compared in this outcome measure. GMT paired ratio (given in statistical analysis section) was calculated by dividing geometric mean values of Group 1a: 28 days post 12 months booster dose in STAGE-II by Group 1: 28 days post-dose 3 in STAGE-I.</description>
          <population>Analysis was performed on PPAS. Here, 'Overall number of participant analyzed'=participants with available data for this outcome measure.</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>98.75% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="853" lower_limit="526" upper_limit="1384"/>
                    <measurement group_id="O2" value="483" lower_limit="281" upper_limit="832"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1186" lower_limit="809" upper_limit="1738"/>
                    <measurement group_id="O2" value="884" lower_limit="602" upper_limit="1300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="696" lower_limit="483" upper_limit="1002"/>
                    <measurement group_id="O2" value="722" lower_limit="458" upper_limit="1140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="592" lower_limit="400" upper_limit="876"/>
                    <measurement group_id="O2" value="383" lower_limit="269" upper_limit="545"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Group 1a Booster/Group 1 Post-dose 3: Serotype 1</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority was demonstrated if the lower limit of the two-sided 95% CI of the ratio of GMTs within groups (Group 1a Booster/Group 1) was &gt;1/2. Overall non-inferiority was demonstrated if all 4 serotypes achieved non-inferiority.</non_inferiority_desc>
            <param_type>GMT paired ratio</param_type>
            <param_value>0.567</param_value>
            <ci_percent>98.75</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.399</ci_lower_limit>
            <ci_upper_limit>0.805</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Group 1a Booster/Group 1 Post-dose 3: Serotype 2</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority was demonstrated if the lower limit of the two-sided 95% CI of the ratio of GMTs within groups (Group 1a Booster/Group 1) was &gt;1/2. Overall non-inferiority was demonstrated if all 4 serotypes achieved non-inferiority.</non_inferiority_desc>
            <param_type>GMT paired ratio</param_type>
            <param_value>0.746</param_value>
            <ci_percent>98.75</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.550</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Group 1a Booster/Group 1 Post-dose 3: Serotype 3</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority was demonstrated if the lower limit of the two-sided 95% CI of the ratio of GMTs within groups (Group 1a Booster/Group 1) was &gt;1/2. Overall non-inferiority was demonstrated if all 4 serotypes achieved non-inferiority.</non_inferiority_desc>
            <param_type>GMT paired ratio</param_type>
            <param_value>1.04</param_value>
            <ci_percent>98.75</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.686</ci_lower_limit>
            <ci_upper_limit>1.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Group 1a Booster/Group 1 Post-dose 3: Serotype 4</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority was demonstrated if the lower limit of the two-sided 95% CI of the ratio of GMTs within groups (Group 1a Booster/Group 1) was &gt;1/2. Overall non-inferiority was demonstrated if all 4 serotypes achieved non-inferiority.</non_inferiority_desc>
            <param_type>GMT paired ratio</param_type>
            <param_value>0.647</param_value>
            <ci_percent>98.75</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.434</ci_lower_limit>
            <ci_upper_limit>0.963</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>STAGE-II: Geometric Mean Titers Against Each Dengue Virus Serotype Comparison Between Group 2a and Group 1 After the Third Dose of CYD Dengue Vaccination in Participants Who Were Seropositive at Baseline</title>
        <description>GMTs of antibodies against each of the 4 dengue virus serotypes (1, 2, 3 or 4) were assessed using the PRNT assay method. Titers were measured in terms of 1/dilution. Dengue seropositive participants at Baseline were defined as participants with titers &gt;=10 (1/dilution) for at least one serotype with the parental dengue virus strains. Data of Group 1 (28 days post-dose 3 in STAGE-I) and Group 2a (28 days post 12 months Booster dose) were reported and compared in this outcome measure. GMT ratio (given in statistical analysis section) was calculated by dividing geometric mean values of Group 2a: 28 days post 12 months booster dose in STAGE-II by Group 1: 28 days Post-dose 3 in STAGE-I.</description>
        <time_frame>Group 1: 28 days post-dose 3 in STAGE-I, Group 2a: 28 days post 12 months booster dose in STAGE-II</time_frame>
        <population>Analysis was performed on PPAS. Here, 'Overall number of participant analyzed'=participants with available data for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: CYD Dengue Vaccine-28 Days Post-dose 3 in STAGE-I</title>
            <description>Participants who received 3 doses of CYD dengue vaccine in STAGE-I, and were seropositive at Baseline were assessed 28 days after third CYD vaccine in STAGE-I.</description>
          </group>
          <group group_id="O2">
            <title>Group 2a: CYD Dengue Vaccine-28 Days Post 12 Months Booster Dose</title>
            <description>Participants from Group 2 (STAGE-I) who were seropositive at Baseline and received a booster dose at 1 year (or 12 months) post last dose in STAGE-I, were assessed 28 days after CYD dengue booster dose vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>STAGE-II: Geometric Mean Titers Against Each Dengue Virus Serotype Comparison Between Group 2a and Group 1 After the Third Dose of CYD Dengue Vaccination in Participants Who Were Seropositive at Baseline</title>
          <description>GMTs of antibodies against each of the 4 dengue virus serotypes (1, 2, 3 or 4) were assessed using the PRNT assay method. Titers were measured in terms of 1/dilution. Dengue seropositive participants at Baseline were defined as participants with titers &gt;=10 (1/dilution) for at least one serotype with the parental dengue virus strains. Data of Group 1 (28 days post-dose 3 in STAGE-I) and Group 2a (28 days post 12 months Booster dose) were reported and compared in this outcome measure. GMT ratio (given in statistical analysis section) was calculated by dividing geometric mean values of Group 2a: 28 days post 12 months booster dose in STAGE-II by Group 1: 28 days Post-dose 3 in STAGE-I.</description>
          <population>Analysis was performed on PPAS. Here, 'Overall number of participant analyzed'=participants with available data for this outcome measure.</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>98.75% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="875" lower_limit="614" upper_limit="1248"/>
                    <measurement group_id="O2" value="549" lower_limit="331" upper_limit="911"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1023" lower_limit="771" upper_limit="1356"/>
                    <measurement group_id="O2" value="828" lower_limit="569" upper_limit="1203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="568" lower_limit="433" upper_limit="745"/>
                    <measurement group_id="O2" value="676" lower_limit="436" upper_limit="1049"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="540" lower_limit="418" upper_limit="697"/>
                    <measurement group_id="O2" value="270" lower_limit="200" upper_limit="364"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Group 2a Booster dose/Group 1 Post-dose 3: Serotype 1</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority was demonstrated if the lower limit of the two-sided Bonferroni corrected 95% CI for the ratio of GMTs between groups (Group 2a Booster/Group 1) was &gt;1/2. Overall non-inferiority was demonstrated if all 4 serotypes achieved non-inferiority.</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.627</param_value>
            <ci_percent>98.75</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.342</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Group 2a Booster/Group 1 Post-dose 3: Serotype 2</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority was demonstrated if the lower limit of the two-sided Bonferroni corrected 95% CI for the ratio of GMTs between groups (Group 2a Booster/Group 1) was &gt;1/2. Overall non-inferiority was demonstrated if all 4 serotypes achieved non-inferiority.</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.809</param_value>
            <ci_percent>98.75</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.505</ci_lower_limit>
            <ci_upper_limit>1.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Group 2a Booster/Group 1 Post-dose 3: Serotype 3</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority was demonstrated if the lower limit of the two-sided Bonferroni corrected 95% CI for the ratio of GMTs between groups (Group 2a Booster/Group 1) was &gt;1/2. Overall non-inferiority was demonstrated if all 4 serotypes achieved non-inferiority.</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>1.19</param_value>
            <ci_percent>98.75</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.732</ci_lower_limit>
            <ci_upper_limit>1.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Group 2a Booster/Group 1 Post-dose 3: Serotype 4</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority was demonstrated if the lower limit of the two-sided Bonferroni corrected 95% CI for the ratio of GMTs between groups (Group 2a Booster/Group 1) was &gt;1/2. Overall non-inferiority was demonstrated if all 4 serotypes achieved non-inferiority.</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.499</param_value>
            <ci_percent>98.75</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.331</ci_lower_limit>
            <ci_upper_limit>0.754</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>STAGE-II: Geometric Mean Titers Against Each Dengue Virus Serotype Within Group 1b and Group 1 After the Third Dose of CYD Dengue Vaccination in Participants Who Were Seropositive at Baseline</title>
        <description>GMTs of antibodies against each of the 4 dengue virus serotypes (1, 2, 3 or 4) were assessed using the PRNT assay method. Titers were measured in terms of 1/dilution. Dengue seropositive participants at Baseline were defined as participants with titers &gt;=10 (1/dilution) for at least one serotype with the parental dengue virus strains. Data of Group 1 (28 days post-dose 3 in STAGE-I) and Group 1b (28 days post 24 months booster dose) were reported and compared in this outcome measure. GMT paired ratio (given in statistical analysis section) was calculated by dividing geometric mean values of Group 1b: 28 days post 24 months booster dose in STAGE-II by Group 1: 28 days Post-dose 3 in STAGE-I.</description>
        <time_frame>Group 1: 28 days post-dose 3 in STAGE-I, Group 1b: 28 days post 24 months booster dose in STAGE-II</time_frame>
        <population>Analysis was performed on PPAS. Here, 'Overall number of participant analyzed'=participants with available data for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: CYD Dengue Vaccine-28 Days Post-dose 3 in STAGE-I</title>
            <description>Participants who received 3 doses of CYD dengue vaccine in STAGE-I, and were seropositive at Baseline were assessed 28 days after third CYD vaccine in STAGE-I.</description>
          </group>
          <group group_id="O2">
            <title>Group 1b: CYD Dengue Vaccine-28 Days Post 24 Month Booster Dose</title>
            <description>Participants from Group 1 (STAGE-I) who were seropositive at Baseline and received a booster dose at 2 years (or 24 months) post last dose in STAGE-I, were assessed 28 days after CYD dengue booster dose vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>STAGE-II: Geometric Mean Titers Against Each Dengue Virus Serotype Within Group 1b and Group 1 After the Third Dose of CYD Dengue Vaccination in Participants Who Were Seropositive at Baseline</title>
          <description>GMTs of antibodies against each of the 4 dengue virus serotypes (1, 2, 3 or 4) were assessed using the PRNT assay method. Titers were measured in terms of 1/dilution. Dengue seropositive participants at Baseline were defined as participants with titers &gt;=10 (1/dilution) for at least one serotype with the parental dengue virus strains. Data of Group 1 (28 days post-dose 3 in STAGE-I) and Group 1b (28 days post 24 months booster dose) were reported and compared in this outcome measure. GMT paired ratio (given in statistical analysis section) was calculated by dividing geometric mean values of Group 1b: 28 days post 24 months booster dose in STAGE-II by Group 1: 28 days Post-dose 3 in STAGE-I.</description>
          <population>Analysis was performed on PPAS. Here, 'Overall number of participant analyzed'=participants with available data for this outcome measure.</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>98.75% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1017" lower_limit="592" upper_limit="1746"/>
                    <measurement group_id="O2" value="700" lower_limit="401" upper_limit="1220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="838" lower_limit="554" upper_limit="1269"/>
                    <measurement group_id="O2" value="730" lower_limit="497" upper_limit="1071"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="486" lower_limit="333" upper_limit="708"/>
                    <measurement group_id="O2" value="559" lower_limit="395" upper_limit="792"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="556" lower_limit="400" upper_limit="774"/>
                    <measurement group_id="O2" value="364" lower_limit="260" upper_limit="510"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Group 1b Booster/Group 1 Post-dose 3: Serotype 1</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority was demonstrated if the lower limit of the two-sided 95% CI of the ratio of GMTs within groups (Group 1b booster/Group 1) was &gt;1/2. Overall non-inferiority was demonstrated if all 4 serotypes achieved non-inferiority.</non_inferiority_desc>
            <param_type>GMT paired ratio</param_type>
            <param_value>0.688</param_value>
            <ci_percent>98.75</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.479</ci_lower_limit>
            <ci_upper_limit>0.989</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Group 1b Booster/Group 1 Post-dose 3: Serotype 2</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority was demonstrated if the lower limit of the two-sided 95% CI of the ratio of GMTs within groups (Group 1b booster/Group 1) was &gt;1/2. Overall non-inferiority was demonstrated if all 4 serotypes achieved non-inferiority.</non_inferiority_desc>
            <param_type>GMT paired ratio</param_type>
            <param_value>0.871</param_value>
            <ci_percent>98.75</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.673</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Group 1b Booster/Group 1 Post-dose 3: Serotype 3</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority was demonstrated if the lower limit of the two-sided 95% CI of the ratio of GMTs within groups (Group 1b booster/Group 1) was &gt;1/2. Overall non-inferiority was demonstrated if all 4 serotypes achieved non-inferiority.</non_inferiority_desc>
            <param_type>GMT paired ratio</param_type>
            <param_value>1.15</param_value>
            <ci_percent>98.75</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.887</ci_lower_limit>
            <ci_upper_limit>1.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Group 1b Booster/Group 1 Post-dose 3: Serotype 4</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority was demonstrated if the lower limit of the two-sided 95% CI of the ratio of GMTs within groups (Group 1b booster/Group 1) was &gt;1/2. Overall non-inferiority was demonstrated if all 4 serotypes achieved non-inferiority.</non_inferiority_desc>
            <param_type>GMT paired ratio</param_type>
            <param_value>0.655</param_value>
            <ci_percent>98.75</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.471</ci_lower_limit>
            <ci_upper_limit>0.911</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>STAGE-II: Geometric Mean Titers Against Each Dengue Virus Serotype Comparison Between Group 2b and Group 1 After the Third Dose of CYD Dengue Vaccination in Participants Who Were Seropositive at Baseline</title>
        <description>GMTs of antibodies against each of the 4 dengue virus serotypes (1, 2, 3 or 4) were assessed using the PRNT assay method. Titers were measured in terms of 1/dilution. Dengue seropositive participants at Baseline were defined as participants with titers &gt;=10 (1/dilution) for at least one serotype with the parental dengue virus strains. Data of Group 1 (28 days post-dose 3 in STAGE-I) and Group 2b (28 days post 24 months Booster dose) was reported and compared in this outcome measure. GMT ratio (given in statistical analysis section) was calculated by dividing geometric mean values of Group 2b: 28 days post 24 months booster dose in STAGE-II by Group 1: 28 days post-dose 3 in STAGE-I.</description>
        <time_frame>Group 1: 28 days post-dose 3 in STAGE-I, Group 2b: 28 days post 24 months Booster dose in STAGE-II</time_frame>
        <population>Analysis was performed on PPAS. Here, 'Overall number of participant analyzed'=participants with available data for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Group 1: CYD Dengue Vaccine-28 Days Post-dose 3 in STAGE-I</title>
            <description>Participants who received 3 doses of CYD dengue vaccine in STAGE-I, and were seropositive at Baseline were assessed 28 days after third CYD vaccine in STAGE-I.</description>
          </group>
          <group group_id="O2">
            <title>Group 2b: CYD Dengue Vaccine-28 Days Post 24 Month Booster Dose</title>
            <description>Participants from Group 1 (STAGE-I) who were seropositive at Baseline and received a booster dose at 2 years (or 24 months) post last dose in STAGE-I, were assessed 28 days after CYD dengue booster dose vaccination.</description>
          </group>
        </group_list>
        <measure>
          <title>STAGE-II: Geometric Mean Titers Against Each Dengue Virus Serotype Comparison Between Group 2b and Group 1 After the Third Dose of CYD Dengue Vaccination in Participants Who Were Seropositive at Baseline</title>
          <description>GMTs of antibodies against each of the 4 dengue virus serotypes (1, 2, 3 or 4) were assessed using the PRNT assay method. Titers were measured in terms of 1/dilution. Dengue seropositive participants at Baseline were defined as participants with titers &gt;=10 (1/dilution) for at least one serotype with the parental dengue virus strains. Data of Group 1 (28 days post-dose 3 in STAGE-I) and Group 2b (28 days post 24 months Booster dose) was reported and compared in this outcome measure. GMT ratio (given in statistical analysis section) was calculated by dividing geometric mean values of Group 2b: 28 days post 24 months booster dose in STAGE-II by Group 1: 28 days post-dose 3 in STAGE-I.</description>
          <population>Analysis was performed on PPAS. Here, 'Overall number of participant analyzed'=participants with available data for this outcome measure.</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>98.75% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="875" lower_limit="614" upper_limit="1248"/>
                    <measurement group_id="O2" value="778" lower_limit="429" upper_limit="1414"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1023" lower_limit="771" upper_limit="1356"/>
                    <measurement group_id="O2" value="692" lower_limit="430" upper_limit="1116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="568" lower_limit="433" upper_limit="745"/>
                    <measurement group_id="O2" value="517" lower_limit="365" upper_limit="733"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="540" lower_limit="418" upper_limit="697"/>
                    <measurement group_id="O2" value="379" lower_limit="261" upper_limit="551"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Group 2b Booster/Group 1 Post-dose 3: Serotype 1</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority was demonstrated if the lower limit of the two-sided 95% CI of the ratio of GMTs between groups (Group 2b Booster/Group 1) was &gt;1/2. Overall non-inferiority was demonstrated if all 4 serotypes achieved non-inferiority.</non_inferiority_desc>
            <param_type>GMT ratio</param_type>
            <param_value>0.889</param_value>
            <ci_percent>98.75</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.462</ci_lower_limit>
            <ci_upper_limit>1.71</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Group 2b Booster/Group 1 Post-dose 3: Serotype 2</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority was demonstrated if the lower limit of the two-sided 95% CI of the ratio of GMTs between groups (Group 2b Booster/Group 1) was &gt;1/2. Overall non-inferiority was demonstrated if all 4 serotypes achieved non-inferiority.</non_inferiority_desc>
            <param_type>GMT ratio</param_type>
            <param_value>0.677</param_value>
            <ci_percent>98.75</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.402</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Group 2b Booster/Group 1 Post-dose 3: Serotype 3</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority was demonstrated if the lower limit of the two-sided 95% CI of the ratio of GMTs between groups (Group 2b Booster/Group 1) was &gt;1/2. Overall non-inferiority was demonstrated if all 4 serotypes achieved non-inferiority.</non_inferiority_desc>
            <param_type>GMT ratio</param_type>
            <param_value>0.911</param_value>
            <ci_percent>98.75</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.573</ci_lower_limit>
            <ci_upper_limit>1.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Group 2b Booster/Group 1 Post-dose 3: Serotype 4</groups_desc>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>The non-inferiority was demonstrated if the lower limit of the two-sided 95% CI of the ratio of GMTs between groups (Group 2b Booster/Group 1) was &gt;1/2. Overall non-inferiority was demonstrated if all 4 serotypes achieved non-inferiority.</non_inferiority_desc>
            <param_type>GMT ratio</param_type>
            <param_value>0.702</param_value>
            <ci_percent>98.75</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.447</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>STAGE-I: Geometric Mean Titers Against Each Serotype With the Parental Dengue Virus Strains After CYD Dengue Vaccination in Participants Who Were Seropositive at Baseline-Comparison Between Group 1 and Group 2</title>
        <description>GMTs of antibodies against each of the 4 dengue virus serotypes (1, 2, 3 or 4) were assessed using the PRNT assay method. Titers were measured in terms of 1/dilution. Dengue seropositive participants at Baseline were defined as participants with titers &gt;=10 (1/dilution) for at least one serotype with the parental dengue virus strains.</description>
        <time_frame>28 days and 1 year after last CYD dengue vaccination</time_frame>
        <population>Analysis was performed on FAS population included participants who had received either at least 1 injection of CYD dengue vaccine or placebo; and had at least 1 blood sample drawn and valid post-injection serology results. Here,'Overall number of participant analyzed'=participants with available data for this outcome measure and 'Number analyzed'=participants with available data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>STAGE-I Group 1: CYD Dengue Vaccine</title>
            <description>Participants received 3 doses of CYD dengue vaccine 0.5 mL SC at Day 0 (Vaccination 1), Month 6 (Vaccination 2), and Month 12 (Vaccination 3).</description>
          </group>
          <group group_id="O2">
            <title>STAGE-I Group 2: Placebo + CYD Dengue Vaccine (Months 6,12)</title>
            <description>Participants received a dose of placebo at Day 0 (Vaccination 1) along with 2 doses of CYD dengue vaccine 0.5 mL SC at Month 6 (Vaccination 2) and Month 12 (Vaccination 3).</description>
          </group>
        </group_list>
        <measure>
          <title>STAGE-I: Geometric Mean Titers Against Each Serotype With the Parental Dengue Virus Strains After CYD Dengue Vaccination in Participants Who Were Seropositive at Baseline-Comparison Between Group 1 and Group 2</title>
          <description>GMTs of antibodies against each of the 4 dengue virus serotypes (1, 2, 3 or 4) were assessed using the PRNT assay method. Titers were measured in terms of 1/dilution. Dengue seropositive participants at Baseline were defined as participants with titers &gt;=10 (1/dilution) for at least one serotype with the parental dengue virus strains.</description>
          <population>Analysis was performed on FAS population included participants who had received either at least 1 injection of CYD dengue vaccine or placebo; and had at least 1 blood sample drawn and valid post-injection serology results. Here,'Overall number of participant analyzed'=participants with available data for this outcome measure and 'Number analyzed'=participants with available data for each specified category.</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="281"/>
                <count group_id="O2" value="288"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>28 days after last vaccination: Serotype 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="274"/>
                    <count group_id="O2" value="282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="834" lower_limit="713" upper_limit="975"/>
                    <measurement group_id="O2" value="877" lower_limit="737" upper_limit="1043"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 days after last vaccination: Serotype 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="274"/>
                    <count group_id="O2" value="282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="879" lower_limit="775" upper_limit="997"/>
                    <measurement group_id="O2" value="870" lower_limit="758" upper_limit="1000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 days after last vaccination: Serotype 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="274"/>
                    <count group_id="O2" value="282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="620" lower_limit="545" upper_limit="704"/>
                    <measurement group_id="O2" value="602" lower_limit="529" upper_limit="686"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>28 days after last vaccination: Serotype 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="274"/>
                    <count group_id="O2" value="282"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="527" lower_limit="467" upper_limit="595"/>
                    <measurement group_id="O2" value="507" lower_limit="451" upper_limit="570"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year after last vaccination: Serotype 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="192"/>
                    <count group_id="O2" value="197"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="498" lower_limit="406" upper_limit="611"/>
                    <measurement group_id="O2" value="512" lower_limit="411" upper_limit="638"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year after last vaccination: Serotype 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="192"/>
                    <count group_id="O2" value="197"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="815" lower_limit="702" upper_limit="947"/>
                    <measurement group_id="O2" value="747" lower_limit="622" upper_limit="897"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year after last vaccination: Serotype 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="192"/>
                    <count group_id="O2" value="197"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="477" lower_limit="407" upper_limit="558"/>
                    <measurement group_id="O2" value="444" lower_limit="376" upper_limit="525"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 year after last vaccination: Serotype 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="192"/>
                    <count group_id="O2" value="197"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="263" lower_limit="230" upper_limit="302"/>
                    <measurement group_id="O2" value="241" lower_limit="208" upper_limit="279"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Group2/Group1: Serotype 1 (28 days after last vaccination)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The superiority was demonstrated if the lower limit of the two-sided 95% CI was greater than 1 between groups (Group 2/Group 1). Overall superiority of Group 2 to Group 1 was demonstrated if individual serotype null hypotheses were rejected.</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.833</ci_lower_limit>
            <ci_upper_limit>1.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Group2/Group1: Serotype 2 (28 days after last vaccination)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The superiority was demonstrated if the lower limit of the two-sided 95% CI was greater than 1 between groups (Group 2/Group 1). Overall superiority of Group 2 to Group 1 was demonstrated if individual serotype null hypotheses were rejected.</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.821</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Group2/Group1: Serotype 3 (28 days after last vaccination)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The superiority was demonstrated if the lower limit of the two-sided 95% CI was greater than 1 between groups (Group 2/Group 1). Overall superiority of Group 2 to Group 1 was demonstrated if individual serotype null hypotheses were rejected.</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.972</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.810</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Group2/Group1: Serotype 4 (28 days after last vaccination)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The superiority was demonstrated if the lower limit of the two-sided 95% CI was greater than 1 between groups (Group 2/Group 1). Overall superiority of Group 2 to Group 1 was demonstrated if individual serotype null hypotheses were rejected.</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.963</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.814</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Group2/Group1: Serotype 1 (1 year after last vaccination)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The superiority was demonstrated if the lower limit of the two-sided 95% CI was greater than 1 between groups (Group 2/Group 1). Overall superiority of Group 2 to Group 1 was demonstrated if individual serotype null hypotheses were rejected.</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.762</ci_lower_limit>
            <ci_upper_limit>1.39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Group2/Group1: Serotype 2 (1 year after last vaccination)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The superiority was demonstrated if the lower limit of the two-sided 95% CI was greater than 1 between groups (Group 2/Group 1). Overall superiority of Group 2 to Group 1 was demonstrated if individual serotype null hypotheses were rejected.</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.917</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.724</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Group2/Group1: Serotype 3 (1 year after last vaccination)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The superiority was demonstrated if the lower limit of the two-sided 95% CI was greater than 1 between groups (Group 2/Group 1). Overall superiority of Group 2 to Group 1 was demonstrated if individual serotype null hypotheses were rejected.</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.933</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.742</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Group2/Group1: Serotype 4 (1 year after last vaccination)</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>The superiority was demonstrated if the lower limit of the two-sided 95% CI was greater than 1 between groups (Group 2/Group 1). Overall superiority of Group 2 to Group 1 was demonstrated if individual serotype null hypotheses were rejected.</non_inferiority_desc>
            <param_type>GMT Ratio</param_type>
            <param_value>0.916</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.750</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>STAGE-I: Geometric Mean Titers Against Each Serotype With the Parental Dengue Virus Strains in All Participants</title>
        <description>GMTs of antibodies against each of the 4 dengue virus serotypes (parental strains) were assessed using the PRNT assay method.</description>
        <time_frame>Baseline, 28 days post vaccination 3, and 1 year post vaccination 3</time_frame>
        <population>Analysis was performed on FAS. Here, 'Number analyzed'=participants with available data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>STAGE-I Group 1: CYD Dengue Vaccine</title>
            <description>Participants received 3 doses of CYD dengue vaccine 0.5 mL SC at Day 0 (Vaccination 1), Month 6 (Vaccination 2), and Month 12 (Vaccination 3).</description>
          </group>
          <group group_id="O2">
            <title>STAGE-I Group 2: Placebo + CYD Dengue Vaccine (Months 6,12)</title>
            <description>Participants received a dose of placebo at Day 0 (Vaccination 1) along with 2 doses of CYD dengue vaccine 0.5 mL SC at Month 6 (Vaccination 2) and Month 12 (Vaccination 3).</description>
          </group>
          <group group_id="O3">
            <title>STAGE-I Group 3: Placebo + CYD Dengue Vaccine (Month 12)</title>
            <description>Participants received 2 doses of placebo at Day 0 (Vaccination 1) and Month 6 (Vaccination 2) along with a dose of CYD dengue vaccine 0.5 mL SC at Month 12 (Vaccination 3).</description>
          </group>
        </group_list>
        <measure>
          <title>STAGE-I: Geometric Mean Titers Against Each Serotype With the Parental Dengue Virus Strains in All Participants</title>
          <description>GMTs of antibodies against each of the 4 dengue virus serotypes (parental strains) were assessed using the PRNT assay method.</description>
          <population>Analysis was performed on FAS. Here, 'Number analyzed'=participants with available data for each specified category.</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="333"/>
                <count group_id="O2" value="328"/>
                <count group_id="O3" value="332"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="333"/>
                    <count group_id="O2" value="328"/>
                    <count group_id="O3" value="332"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="131" lower_limit="103" upper_limit="165"/>
                    <measurement group_id="O2" value="187" lower_limit="147" upper_limit="237"/>
                    <measurement group_id="O3" value="198" lower_limit="157" upper_limit="250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 1: 28 days post vaccination 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="326"/>
                    <count group_id="O2" value="322"/>
                    <count group_id="O3" value="324"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="497" lower_limit="410" upper_limit="602"/>
                    <measurement group_id="O2" value="586" lower_limit="482" upper_limit="714"/>
                    <measurement group_id="O3" value="735" lower_limit="589" upper_limit="916"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 1: 1 year post vaccination 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="231"/>
                    <count group_id="O2" value="232"/>
                    <count group_id="O3" value="230"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="259" lower_limit="200" upper_limit="336"/>
                    <measurement group_id="O2" value="279" lower_limit="213" upper_limit="365"/>
                    <measurement group_id="O3" value="331" lower_limit="252" upper_limit="435"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 2: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="333"/>
                    <count group_id="O2" value="328"/>
                    <count group_id="O3" value="332"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="172" lower_limit="138" upper_limit="214"/>
                    <measurement group_id="O2" value="202" lower_limit="163" upper_limit="252"/>
                    <measurement group_id="O3" value="181" lower_limit="147" upper_limit="222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 2: 28 days post vaccination 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="326"/>
                    <count group_id="O2" value="322"/>
                    <count group_id="O3" value="324"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="567" lower_limit="482" upper_limit="666"/>
                    <measurement group_id="O2" value="628" lower_limit="532" upper_limit="741"/>
                    <measurement group_id="O3" value="734" lower_limit="614" upper_limit="878"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 2: 1 year post vaccination 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="231"/>
                    <count group_id="O2" value="232"/>
                    <count group_id="O3" value="230"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="470" lower_limit="380" upper_limit="582"/>
                    <measurement group_id="O2" value="457" lower_limit="364" upper_limit="574"/>
                    <measurement group_id="O3" value="500" lower_limit="402" upper_limit="623"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="333"/>
                    <count group_id="O2" value="328"/>
                    <count group_id="O3" value="332"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="163" lower_limit="131" upper_limit="202"/>
                    <measurement group_id="O2" value="180" lower_limit="145" upper_limit="222"/>
                    <measurement group_id="O3" value="169" lower_limit="138" upper_limit="207"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3: 28 days post vaccination 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="326"/>
                    <count group_id="O2" value="322"/>
                    <count group_id="O3" value="324"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="432" lower_limit="373" upper_limit="500"/>
                    <measurement group_id="O2" value="446" lower_limit="383" upper_limit="519"/>
                    <measurement group_id="O3" value="505" lower_limit="428" upper_limit="595"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3: 1 year post vaccination 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="231"/>
                    <count group_id="O2" value="232"/>
                    <count group_id="O3" value="230"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="294" lower_limit="240" upper_limit="361"/>
                    <measurement group_id="O2" value="288" lower_limit="235" upper_limit="354"/>
                    <measurement group_id="O3" value="258" lower_limit="213" upper_limit="312"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="333"/>
                    <count group_id="O2" value="328"/>
                    <count group_id="O3" value="332"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.7" lower_limit="71.4" upper_limit="105"/>
                    <measurement group_id="O2" value="83.8" lower_limit="69.9" upper_limit="100"/>
                    <measurement group_id="O3" value="81.2" lower_limit="67.7" upper_limit="97.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4: 28 days post vaccination 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="326"/>
                    <count group_id="O2" value="322"/>
                    <count group_id="O3" value="324"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="429" lower_limit="380" upper_limit="484"/>
                    <measurement group_id="O2" value="441" lower_limit="392" upper_limit="496"/>
                    <measurement group_id="O3" value="546" lower_limit="475" upper_limit="629"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4: 1 year post vaccination 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="231"/>
                    <count group_id="O2" value="232"/>
                    <count group_id="O3" value="230"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="203" lower_limit="176" upper_limit="235"/>
                    <measurement group_id="O2" value="192" lower_limit="164" upper_limit="226"/>
                    <measurement group_id="O3" value="177" lower_limit="150" upper_limit="210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>STAGE-I: Geometric Mean Titers Against Each Serotype With the Parental Dengue Virus Strains (by Baseline Dengue Status) in Participants Who Were Seropositive and Seronegative at Baseline</title>
        <description>GMTs of antibodies against each of the 4 dengue virus serotypes (1, 2, 3, or 4) were assessed using the PRNT assay method. Titers were measured in terms of 1/dilution. Dengue seropositive participants at Baseline were defined as participants with titers &gt;=10 (1/dilution) for at least one serotype with the parental dengue virus strains. Dengue seronegative participants at Baseline were defined as the participants with valid titer &lt;0 (1/dilution) for all serotypes with parental dengue virus strains.</description>
        <time_frame>Baseline, 28 days post vaccination 3, and 1 year post vaccination 3</time_frame>
        <population>Analysis was performed on FAS. Here, 'Overall number of participants analyzed'=participants evaluable for this outcome measure and 'Number analyzed'=participants with available data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>STAGE-I Group 1: CYD Dengue Vaccine</title>
            <description>Participants received 3 doses of CYD dengue vaccine 0.5 mL SC at Day 0 (Vaccination 1), Month 6 (Vaccination 2), and Month 12 (Vaccination 3).</description>
          </group>
          <group group_id="O2">
            <title>STAGE-I Group 2: Placebo + CYD Dengue Vaccine (Months 6,12)</title>
            <description>Participants received a dose of placebo at Day 0 (Vaccination 1) along with 2 doses of CYD dengue vaccine 0.5 mL SC at Month 6 (Vaccination 2) and Month 12 (Vaccination 3).</description>
          </group>
          <group group_id="O3">
            <title>STAGE-I Group 3: Placebo + CYD Dengue Vaccine (Month 12)</title>
            <description>Participants received 2 doses of placebo at Day 0 (Vaccination 1) and Month 6 (Vaccination 2) along with a dose of CYD dengue vaccine 0.5 mL SC at Month 12 (Vaccination 3).</description>
          </group>
        </group_list>
        <measure>
          <title>STAGE-I: Geometric Mean Titers Against Each Serotype With the Parental Dengue Virus Strains (by Baseline Dengue Status) in Participants Who Were Seropositive and Seronegative at Baseline</title>
          <description>GMTs of antibodies against each of the 4 dengue virus serotypes (1, 2, 3, or 4) were assessed using the PRNT assay method. Titers were measured in terms of 1/dilution. Dengue seropositive participants at Baseline were defined as participants with titers &gt;=10 (1/dilution) for at least one serotype with the parental dengue virus strains. Dengue seronegative participants at Baseline were defined as the participants with valid titer &lt;0 (1/dilution) for all serotypes with parental dengue virus strains.</description>
          <population>Analysis was performed on FAS. Here, 'Overall number of participants analyzed'=participants evaluable for this outcome measure and 'Number analyzed'=participants with available data for each specified category.</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="281"/>
                <count group_id="O2" value="288"/>
                <count group_id="O3" value="291"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Seropositive- Serotype 1: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="281"/>
                    <count group_id="O2" value="288"/>
                    <count group_id="O3" value="291"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="239" lower_limit="194" upper_limit="295"/>
                    <measurement group_id="O2" value="304" lower_limit="244" upper_limit="379"/>
                    <measurement group_id="O3" value="328" lower_limit="267" upper_limit="404"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seropositive- Serotype 1: 28 days post vaccination 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="274"/>
                    <count group_id="O2" value="282"/>
                    <count group_id="O3" value="285"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="834" lower_limit="713" upper_limit="975"/>
                    <measurement group_id="O2" value="877" lower_limit="737" upper_limit="1043"/>
                    <measurement group_id="O3" value="1201" lower_limit="1007" upper_limit="1431"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seropositive- Serotype 1: 1 year post vaccination 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="192"/>
                    <count group_id="O2" value="197"/>
                    <count group_id="O3" value="197"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="498" lower_limit="406" upper_limit="611"/>
                    <measurement group_id="O2" value="512" lower_limit="411" upper_limit="638"/>
                    <measurement group_id="O3" value="618" lower_limit="500" upper_limit="764"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seropositive- Serotype 2: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="281"/>
                    <count group_id="O2" value="288"/>
                    <count group_id="O3" value="291"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="331" lower_limit="279" upper_limit="394"/>
                    <measurement group_id="O2" value="326" lower_limit="271" upper_limit="393"/>
                    <measurement group_id="O3" value="293" lower_limit="247" upper_limit="347"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seropositive- Serotype 2: 28 days post vaccination 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="274"/>
                    <count group_id="O2" value="282"/>
                    <count group_id="O3" value="285"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="879" lower_limit="775" upper_limit="997"/>
                    <measurement group_id="O2" value="870" lower_limit="758" upper_limit="1000"/>
                    <measurement group_id="O3" value="1046" lower_limit="912" upper_limit="1201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seropositive- Serotype 2: 1 year post vaccination 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="192"/>
                    <count group_id="O2" value="197"/>
                    <count group_id="O3" value="197"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="815" lower_limit="702" upper_limit="947"/>
                    <measurement group_id="O2" value="747" lower_limit="622" upper_limit="897"/>
                    <measurement group_id="O3" value="798" lower_limit="676" upper_limit="942"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seropositive- Serotype 3: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="281"/>
                    <count group_id="O2" value="288"/>
                    <count group_id="O3" value="291"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="310" lower_limit="263" upper_limit="367"/>
                    <measurement group_id="O2" value="290" lower_limit="241" upper_limit="349"/>
                    <measurement group_id="O3" value="269" lower_limit="227" upper_limit="319"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seropositive- Serotype 3: 28 days post vaccination 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="274"/>
                    <count group_id="O2" value="282"/>
                    <count group_id="O3" value="285"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="620" lower_limit="545" upper_limit="704"/>
                    <measurement group_id="O2" value="602" lower_limit="529" upper_limit="686"/>
                    <measurement group_id="O3" value="694" lower_limit="604" upper_limit="797"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seropositive- Serotype 3: 1 year post vaccination 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="192"/>
                    <count group_id="O2" value="197"/>
                    <count group_id="O3" value="197"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="477" lower_limit="407" upper_limit="558"/>
                    <measurement group_id="O2" value="444" lower_limit="376" upper_limit="525"/>
                    <measurement group_id="O3" value="390" lower_limit="338" upper_limit="450"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seropositive- Serotype 4: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="281"/>
                    <count group_id="O2" value="288"/>
                    <count group_id="O3" value="291"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147" lower_limit="124" upper_limit="174"/>
                    <measurement group_id="O2" value="123" lower_limit="104" upper_limit="144"/>
                    <measurement group_id="O3" value="118" lower_limit="100" upper_limit="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seropositive- Serotype 4: 28 days post vaccination 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="274"/>
                    <count group_id="O2" value="282"/>
                    <count group_id="O3" value="285"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="527" lower_limit="467" upper_limit="595"/>
                    <measurement group_id="O2" value="507" lower_limit="451" upper_limit="570"/>
                    <measurement group_id="O3" value="581" lower_limit="507" upper_limit="666"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seropositive- Serotype 4: 1 year post vaccination 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="192"/>
                    <count group_id="O2" value="197"/>
                    <count group_id="O3" value="197"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="263" lower_limit="230" upper_limit="302"/>
                    <measurement group_id="O2" value="241" lower_limit="208" upper_limit="279"/>
                    <measurement group_id="O3" value="227" lower_limit="194" upper_limit="265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seronegative- Serotype 1: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.00" lower_limit="NA" upper_limit="NA">The 95% CI was not computable as the standard deviation of the sample was 0, since all participants had the same value.</measurement>
                    <measurement group_id="O2" value="5.57" lower_limit="4.65" upper_limit="6.67"/>
                    <measurement group_id="O3" value="5.49" lower_limit="4.75" upper_limit="6.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seronegative- Serotype 1: 28 days post vaccination 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.4" lower_limit="23.1" upper_limit="45.6"/>
                    <measurement group_id="O2" value="34.3" lower_limit="23.8" upper_limit="49.4"/>
                    <measurement group_id="O3" value="20.2" lower_limit="12.0" upper_limit="34.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seronegative- Serotype 1: 1 year post vaccination 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4" lower_limit="7.12" upper_limit="15.1"/>
                    <measurement group_id="O2" value="9.01" lower_limit="6.30" upper_limit="12.9"/>
                    <measurement group_id="O3" value="8.04" lower_limit="5.86" upper_limit="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seronegative- Serotype 2: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.00" lower_limit="NA" upper_limit="NA">The 95% CI was not computable as the standard deviation of the sample was 0, since all participants had the same value.</measurement>
                    <measurement group_id="O2" value="6.47" lower_limit="4.43" upper_limit="9.45"/>
                    <measurement group_id="O3" value="5.86" lower_limit="4.99" upper_limit="6.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seronegative- Serotype 2: 28 days post vaccination 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.2" lower_limit="40.1" upper_limit="78.7"/>
                    <measurement group_id="O2" value="63.0" lower_limit="37.5" upper_limit="106"/>
                    <measurement group_id="O3" value="55.2" lower_limit="27.8" upper_limit="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seronegative- Serotype 2: 1 year post vaccination 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.3" lower_limit="20.2" upper_limit="48.6"/>
                    <measurement group_id="O2" value="28.7" lower_limit="17.3" upper_limit="47.7"/>
                    <measurement group_id="O3" value="30.9" lower_limit="17.5" upper_limit="54.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seronegative- Serotype 3: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.00" lower_limit="NA" upper_limit="NA">The 95% CI was not computable as the standard deviation of the sample was 0, since all participants had the same value.</measurement>
                    <measurement group_id="O2" value="5.69" lower_limit="4.86" upper_limit="6.66"/>
                    <measurement group_id="O3" value="6.09" lower_limit="5.05" upper_limit="7.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seronegative- Serotype 3: 28 days post vaccination 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.2" lower_limit="48.6" upper_limit="84.9"/>
                    <measurement group_id="O2" value="53.7" lower_limit="36.1" upper_limit="80.0"/>
                    <measurement group_id="O3" value="49.5" lower_limit="30.1" upper_limit="81.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seronegative- Serotype 3: 1 year post injection 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.5" lower_limit="17.4" upper_limit="43.5"/>
                    <measurement group_id="O2" value="25.3" lower_limit="15.8" upper_limit="40.3"/>
                    <measurement group_id="O3" value="21.8" lower_limit="13.6" upper_limit="35.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seronegative- Serotype 4: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.00" lower_limit="NA" upper_limit="NA">The 95% CI was not computable as the standard deviation of the sample was 0, since all participants had the same value.</measurement>
                    <measurement group_id="O2" value="5.41" lower_limit="4.61" upper_limit="6.35"/>
                    <measurement group_id="O3" value="5.64" lower_limit="4.90" upper_limit="6.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seronegative- Serotype 4: 28 days post vaccination 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="40"/>
                    <count group_id="O3" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145" lower_limit="112" upper_limit="187"/>
                    <measurement group_id="O2" value="164" lower_limit="114" upper_limit="237"/>
                    <measurement group_id="O3" value="349" lower_limit="189" upper_limit="646"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seronegative- Serotype 4: 1 year post vaccination 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="35"/>
                    <count group_id="O3" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.1" lower_limit="42.5" upper_limit="76.8"/>
                    <measurement group_id="O2" value="53.8" lower_limit="32.0" upper_limit="90.5"/>
                    <measurement group_id="O3" value="40.8" lower_limit="24.9" upper_limit="66.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>STAGE-II: Geometric Mean Titers Against Each Serotype With the Parental Dengue Virus Strains After Booster CYD Dengue Vaccination in Participants Seropositive at Baseline</title>
        <description>GMTs of antibodies against each of the 4 dengue virus serotype (1, 2, 3, or 4) were assessed using the PRNT assay. Dengue seropositive participants at Baseline were defined as participants with titers &gt;=10 (1/dilution) for at least one serotype with the parental dengue virus strains. Titers were measured in terms of 1/dilution.</description>
        <time_frame>Baseline, 28 days post vaccination-3, and 28 days post booster dose</time_frame>
        <population>Analysis was performed on FAS. Here, 'Overall number of participant analyzed'=participants with available data for this outcome measure and 'Number analyzed'=participants with available data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>STAGE-II Group 1a: CYD Vaccine + CYD Booster Vaccine (1 Year)</title>
            <description>Participants from Group 1 who received vaccination in STAGE-I; and were seropositive at Baseline received a booster dose of CYD dengue vaccine in STAGE-II at 1 year post last dose in STAGE-I (i.e., at Month 24).</description>
          </group>
          <group group_id="O2">
            <title>STAGE-II Group 2a: Placebo + CYD + CYD Booster (1 Year)</title>
            <description>Participants from Group 2 who received vaccination in STAGE-I and were seropositive at baseline received a booster injection of CYD dengue vaccine in STAGE-II at 1 year post last dose in STAGE-I (i.e., at Month 24).</description>
          </group>
          <group group_id="O3">
            <title>STAGE-II Group 3a: Placebo + CYD + CYD Booster (1 Year)</title>
            <description>Participants from Group 3 who received vaccination in STAGE-I and were seropositive at baseline received a booster injection of CYD dengue vaccine in STAGE-II at 1 year post last dose in STAGE-I (i.e., at Month 24).</description>
          </group>
          <group group_id="O4">
            <title>STAGE-II Group 1b: CYD Vaccine + CYD Booster Vaccine (2 Years)</title>
            <description>Participants from Group 1 who received vaccination in STAGE-I and were seropositive at baseline received a booster injection of CYD dengue vaccine in STAGE-II at 2 years post last dose in STAGE-I (i.e., at Month 36).</description>
          </group>
          <group group_id="O5">
            <title>STAGE-II Group 2b: Placebo + CYD + CYD Booster (2 Years)</title>
            <description>Participants from Group 2 who received vaccination in STAGE-I and were seropositive at baseline received a booster injection of CYD dengue vaccine in STAGE-II at 2 years post last dose in STAGE-I (i.e., at Month 36).</description>
          </group>
          <group group_id="O6">
            <title>STAGE-II Group 3b: Placebo + CYD + CYD Booster (2 Years)</title>
            <description>Participants from Group 3 who received vaccination in STAGE-I and were seropositive at baseline received a booster injection of CYD dengue vaccine in STAGE-II at 2 years post last dose in STAGE-I (i.e., at Month 36).</description>
          </group>
        </group_list>
        <measure>
          <title>STAGE-II: Geometric Mean Titers Against Each Serotype With the Parental Dengue Virus Strains After Booster CYD Dengue Vaccination in Participants Seropositive at Baseline</title>
          <description>GMTs of antibodies against each of the 4 dengue virus serotype (1, 2, 3, or 4) were assessed using the PRNT assay. Dengue seropositive participants at Baseline were defined as participants with titers &gt;=10 (1/dilution) for at least one serotype with the parental dengue virus strains. Titers were measured in terms of 1/dilution.</description>
          <population>Analysis was performed on FAS. Here, 'Overall number of participant analyzed'=participants with available data for this outcome measure and 'Number analyzed'=participants with available data for each specified category.</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="144"/>
                <count group_id="O3" value="147"/>
                <count group_id="O4" value="140"/>
                <count group_id="O5" value="144"/>
                <count group_id="O6" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="141"/>
                    <count group_id="O2" value="144"/>
                    <count group_id="O3" value="147"/>
                    <count group_id="O4" value="140"/>
                    <count group_id="O5" value="144"/>
                    <count group_id="O6" value="144"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="246" lower_limit="183" upper_limit="331"/>
                    <measurement group_id="O2" value="283" lower_limit="207" upper_limit="385"/>
                    <measurement group_id="O3" value="309" lower_limit="227" upper_limit="421"/>
                    <measurement group_id="O4" value="231" lower_limit="171" upper_limit="313"/>
                    <measurement group_id="O5" value="327" lower_limit="239" upper_limit="447"/>
                    <measurement group_id="O6" value="350" lower_limit="265" upper_limit="462"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 1: 28 days post vaccination 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="137"/>
                    <count group_id="O2" value="140"/>
                    <count group_id="O3" value="145"/>
                    <count group_id="O4" value="137"/>
                    <count group_id="O5" value="142"/>
                    <count group_id="O6" value="140"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="828" lower_limit="671" upper_limit="1022"/>
                    <measurement group_id="O2" value="933" lower_limit="730" upper_limit="1192"/>
                    <measurement group_id="O3" value="1111" lower_limit="868" upper_limit="1423"/>
                    <measurement group_id="O4" value="840" lower_limit="664" upper_limit="1061"/>
                    <measurement group_id="O5" value="824" lower_limit="644" upper_limit="1056"/>
                    <measurement group_id="O6" value="1301" lower_limit="1011" upper_limit="1675"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 1 : 28 days post booster dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="59"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="53"/>
                    <count group_id="O5" value="54"/>
                    <count group_id="O6" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="505" lower_limit="335" upper_limit="763"/>
                    <measurement group_id="O2" value="552" lower_limit="375" upper_limit="812"/>
                    <measurement group_id="O3" value="861" lower_limit="572" upper_limit="1297"/>
                    <measurement group_id="O4" value="707" lower_limit="472" upper_limit="1057"/>
                    <measurement group_id="O5" value="749" lower_limit="465" upper_limit="1207"/>
                    <measurement group_id="O6" value="1199" lower_limit="755" upper_limit="1902"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 2 : Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="141"/>
                    <count group_id="O2" value="144"/>
                    <count group_id="O3" value="147"/>
                    <count group_id="O4" value="140"/>
                    <count group_id="O5" value="144"/>
                    <count group_id="O6" value="144"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="370" lower_limit="295" upper_limit="466"/>
                    <measurement group_id="O2" value="335" lower_limit="258" upper_limit="437"/>
                    <measurement group_id="O3" value="283" lower_limit="221" upper_limit="363"/>
                    <measurement group_id="O4" value="296" lower_limit="228" upper_limit="385"/>
                    <measurement group_id="O5" value="318" lower_limit="244" upper_limit="413"/>
                    <measurement group_id="O6" value="303" lower_limit="241" upper_limit="382"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 2 : 28 days post vaccination 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="137"/>
                    <count group_id="O2" value="140"/>
                    <count group_id="O3" value="145"/>
                    <count group_id="O4" value="137"/>
                    <count group_id="O5" value="142"/>
                    <count group_id="O6" value="140"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="986" lower_limit="834" upper_limit="1166"/>
                    <measurement group_id="O2" value="897" lower_limit="735" upper_limit="1096"/>
                    <measurement group_id="O3" value="1018" lower_limit="850" upper_limit="1218"/>
                    <measurement group_id="O4" value="783" lower_limit="648" upper_limit="947"/>
                    <measurement group_id="O5" value="844" lower_limit="695" upper_limit="1025"/>
                    <measurement group_id="O6" value="1077" lower_limit="871" upper_limit="1331"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 2 : 28 days post booster dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="59"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="53"/>
                    <count group_id="O5" value="54"/>
                    <count group_id="O6" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="856" lower_limit="638" upper_limit="1147"/>
                    <measurement group_id="O2" value="858" lower_limit="639" upper_limit="1152"/>
                    <measurement group_id="O3" value="867" lower_limit="640" upper_limit="1174"/>
                    <measurement group_id="O4" value="813" lower_limit="600" upper_limit="1100"/>
                    <measurement group_id="O5" value="655" lower_limit="461" upper_limit="931"/>
                    <measurement group_id="O6" value="967" lower_limit="697" upper_limit="1343"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3 : Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="141"/>
                    <count group_id="O2" value="144"/>
                    <count group_id="O3" value="147"/>
                    <count group_id="O4" value="140"/>
                    <count group_id="O5" value="144"/>
                    <count group_id="O6" value="144"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="363" lower_limit="285" upper_limit="462"/>
                    <measurement group_id="O2" value="399" lower_limit="308" upper_limit="519"/>
                    <measurement group_id="O3" value="287" lower_limit="222" upper_limit="371"/>
                    <measurement group_id="O4" value="266" lower_limit="211" upper_limit="335"/>
                    <measurement group_id="O5" value="210" lower_limit="164" upper_limit="271"/>
                    <measurement group_id="O6" value="253" lower_limit="201" upper_limit="317"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3: 28 days post vaccination 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="137"/>
                    <count group_id="O2" value="140"/>
                    <count group_id="O3" value="145"/>
                    <count group_id="O4" value="137"/>
                    <count group_id="O5" value="142"/>
                    <count group_id="O6" value="140"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="733" lower_limit="617" upper_limit="871"/>
                    <measurement group_id="O2" value="659" lower_limit="547" upper_limit="794"/>
                    <measurement group_id="O3" value="725" lower_limit="607" upper_limit="865"/>
                    <measurement group_id="O4" value="524" lower_limit="434" upper_limit="631"/>
                    <measurement group_id="O5" value="551" lower_limit="459" upper_limit="661"/>
                    <measurement group_id="O6" value="663" lower_limit="534" upper_limit="823"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3:28 days post booster dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="59"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="53"/>
                    <count group_id="O5" value="54"/>
                    <count group_id="O6" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="721" lower_limit="511" upper_limit="1018"/>
                    <measurement group_id="O2" value="667" lower_limit="477" upper_limit="933"/>
                    <measurement group_id="O3" value="743" lower_limit="557" upper_limit="992"/>
                    <measurement group_id="O4" value="586" lower_limit="455" upper_limit="754"/>
                    <measurement group_id="O5" value="477" lower_limit="364" upper_limit="626"/>
                    <measurement group_id="O6" value="506" lower_limit="370" upper_limit="691"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="141"/>
                    <count group_id="O2" value="144"/>
                    <count group_id="O3" value="147"/>
                    <count group_id="O4" value="140"/>
                    <count group_id="O5" value="144"/>
                    <count group_id="O6" value="144"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147" lower_limit="114" upper_limit="190"/>
                    <measurement group_id="O2" value="142" lower_limit="113" upper_limit="178"/>
                    <measurement group_id="O3" value="115" lower_limit="89.6" upper_limit="146"/>
                    <measurement group_id="O4" value="147" lower_limit="117" upper_limit="183"/>
                    <measurement group_id="O5" value="106" lower_limit="84.5" upper_limit="133"/>
                    <measurement group_id="O6" value="122" lower_limit="97.3" upper_limit="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4:28 day post vaccination 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="137"/>
                    <count group_id="O2" value="140"/>
                    <count group_id="O3" value="145"/>
                    <count group_id="O4" value="137"/>
                    <count group_id="O5" value="142"/>
                    <count group_id="O6" value="140"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="512" lower_limit="433" upper_limit="605"/>
                    <measurement group_id="O2" value="536" lower_limit="456" upper_limit="631"/>
                    <measurement group_id="O3" value="570" lower_limit="463" upper_limit="701"/>
                    <measurement group_id="O4" value="543" lower_limit="456" upper_limit="647"/>
                    <measurement group_id="O5" value="480" lower_limit="406" upper_limit="568"/>
                    <measurement group_id="O6" value="593" lower_limit="495" upper_limit="711"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4 : 28 days post booster dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="59"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="53"/>
                    <count group_id="O5" value="54"/>
                    <count group_id="O6" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="380" lower_limit="292" upper_limit="495"/>
                    <measurement group_id="O2" value="265" lower_limit="210" upper_limit="334"/>
                    <measurement group_id="O3" value="300" lower_limit="223" upper_limit="405"/>
                    <measurement group_id="O4" value="368" lower_limit="290" upper_limit="466"/>
                    <measurement group_id="O5" value="360" lower_limit="273" upper_limit="474"/>
                    <measurement group_id="O6" value="413" lower_limit="297" upper_limit="574"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>STAGE-I: Percentage of Participants With Antibodies Titer &gt;=10 (1/Dilution) Against Each Serotype With the Parental Dengue Virus Strains in All Participants</title>
        <description>GMTs of antibodies against each of the 4 dengue virus serotypes (1, 2, 3 or 4) were assessed using the PRNT assay.</description>
        <time_frame>Baseline, 28 days post vaccination 3, and 1 year post vaccination 3</time_frame>
        <population>Analysis was performed on FAS. Here, 'Number analyzed'=participants with available data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>STAGE-I Group 1: CYD Dengue Vaccine</title>
            <description>Participants received 3 doses of CYD dengue vaccine 0.5 mL SC at Day 0 (Vaccination 1), Month 6 (Vaccination 2), and Month 12 (Vaccination 3).</description>
          </group>
          <group group_id="O2">
            <title>STAGE-I Group 2: Placebo + CYD Dengue Vaccine (Months 6,12)</title>
            <description>Participants received a dose of placebo at Day 0 (Vaccination 1) along with 2 doses of CYD dengue vaccine 0.5 mL SC at Month 6 (Vaccination 2) and Month 12 (Vaccination 3).</description>
          </group>
          <group group_id="O3">
            <title>STAGE-I Group 3: Placebo + CYD Dengue Vaccine (Month 12)</title>
            <description>Participants received 2 doses of placebo at Day 0 (Vaccination 1) and Month 6 (Vaccination 2) along with a dose of CYD dengue vaccine 0.5 mL SC at Month 12 (Vaccination 3).</description>
          </group>
        </group_list>
        <measure>
          <title>STAGE-I: Percentage of Participants With Antibodies Titer &gt;=10 (1/Dilution) Against Each Serotype With the Parental Dengue Virus Strains in All Participants</title>
          <description>GMTs of antibodies against each of the 4 dengue virus serotypes (1, 2, 3 or 4) were assessed using the PRNT assay.</description>
          <population>Analysis was performed on FAS. Here, 'Number analyzed'=participants with available data for each specified category.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="333"/>
                <count group_id="O2" value="328"/>
                <count group_id="O3" value="332"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="333"/>
                    <count group_id="O2" value="328"/>
                    <count group_id="O3" value="332"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.8" lower_limit="72.9" upper_limit="82.1"/>
                    <measurement group_id="O2" value="80.5" lower_limit="75.8" upper_limit="84.6"/>
                    <measurement group_id="O3" value="83.4" lower_limit="79.0" upper_limit="87.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 1: 28 days post vaccination 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="326"/>
                    <count group_id="O2" value="322"/>
                    <count group_id="O3" value="324"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.3" lower_limit="93.7" upper_limit="98.1"/>
                    <measurement group_id="O2" value="97.2" lower_limit="94.8" upper_limit="98.7"/>
                    <measurement group_id="O3" value="94.1" lower_limit="91.0" upper_limit="96.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 1: 1 year post vaccination 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="231"/>
                    <count group_id="O2" value="232"/>
                    <count group_id="O3" value="230"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.3" lower_limit="83.5" upper_limit="92.2"/>
                    <measurement group_id="O2" value="87.5" lower_limit="82.5" upper_limit="91.5"/>
                    <measurement group_id="O3" value="88.3" lower_limit="83.4" upper_limit="92.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 2: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="333"/>
                    <count group_id="O2" value="328"/>
                    <count group_id="O3" value="332"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.6" lower_limit="78.1" upper_limit="86.5"/>
                    <measurement group_id="O2" value="83.8" lower_limit="79.4" upper_limit="87.7"/>
                    <measurement group_id="O3" value="85.2" lower_limit="81.0" upper_limit="88.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 2: 28 days post vaccination 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="326"/>
                    <count group_id="O2" value="322"/>
                    <count group_id="O3" value="324"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.2" lower_limit="96.0" upper_limit="99.3"/>
                    <measurement group_id="O2" value="96.6" lower_limit="94.0" upper_limit="98.3"/>
                    <measurement group_id="O3" value="96.0" lower_limit="93.2" upper_limit="97.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 2: 1 year post vaccination 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="231"/>
                    <count group_id="O2" value="232"/>
                    <count group_id="O3" value="230"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.7" lower_limit="92.2" upper_limit="97.9"/>
                    <measurement group_id="O2" value="94.4" lower_limit="90.6" upper_limit="97.0"/>
                    <measurement group_id="O3" value="94.8" lower_limit="91.1" upper_limit="97.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="333"/>
                    <count group_id="O2" value="328"/>
                    <count group_id="O3" value="332"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.6" lower_limit="78.1" upper_limit="86.5"/>
                    <measurement group_id="O2" value="84.1" lower_limit="79.7" upper_limit="87.9"/>
                    <measurement group_id="O3" value="87.0" lower_limit="83.0" upper_limit="90.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3: 28 days post vaccination 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="326"/>
                    <count group_id="O2" value="322"/>
                    <count group_id="O3" value="324"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.5" lower_limit="96.5" upper_limit="99.5"/>
                    <measurement group_id="O2" value="98.1" lower_limit="96.0" upper_limit="99.3"/>
                    <measurement group_id="O3" value="97.5" lower_limit="95.2" upper_limit="98.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3: 1 year post vaccination 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="231"/>
                    <count group_id="O2" value="232"/>
                    <count group_id="O3" value="230"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.7" lower_limit="92.2" upper_limit="97.9"/>
                    <measurement group_id="O2" value="95.7" lower_limit="92.2" upper_limit="97.9"/>
                    <measurement group_id="O3" value="94.3" lower_limit="90.5" upper_limit="97.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="333"/>
                    <count group_id="O2" value="328"/>
                    <count group_id="O3" value="332"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.6" lower_limit="74.8" upper_limit="83.8"/>
                    <measurement group_id="O2" value="81.4" lower_limit="76.8" upper_limit="85.5"/>
                    <measurement group_id="O3" value="81.6" lower_limit="77.0" upper_limit="85.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4: 28 days post vaccination 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="326"/>
                    <count group_id="O2" value="322"/>
                    <count group_id="O3" value="324"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.7" lower_limit="98.3" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.4" lower_limit="97.8" upper_limit="99.9"/>
                    <measurement group_id="O3" value="98.8" lower_limit="96.9" upper_limit="99.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4: 1 year post vaccination 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="231"/>
                    <count group_id="O2" value="232"/>
                    <count group_id="O3" value="230"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.1" lower_limit="96.9" upper_limit="99.9"/>
                    <measurement group_id="O2" value="96.6" lower_limit="93.3" upper_limit="98.5"/>
                    <measurement group_id="O3" value="95.7" lower_limit="92.1" upper_limit="97.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>STAGE-II: Percentage of Participants With Antibodies Titer &gt;=10 (1/Dilution) Against Each Serotype With the Parental Dengue Virus Strain in Participants Seropositive at Baseline</title>
        <description>GMTs of antibodies against each of the 4 dengue virus serotypes (1, 2, 3 or 4) were assessed using the PRNT assay method. Dengue seropositive participants at Baseline were defined as participants with titers &gt;=10 (1/dilution) for at least one serotype with the parental dengue virus strains.</description>
        <time_frame>Baseline, 28 days post vaccination 3, and 1 year post vaccination 3</time_frame>
        <population>Analysis was performed on FAS. Here, 'Overall number of participant analyzed'=participants with available data for this outcome measure and 'Number analyzed'=participants with available data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>STAGE-II Group 1a: CYD Vaccine + CYD Booster Vaccine (1 Year)</title>
            <description>Participants from Group 1 who received vaccination in STAGE-I; and were seropositive at Baseline received a booster dose of CYD dengue vaccine in STAGE-II at 1 year post last dose in STAGE-I (i.e., at Month 24).</description>
          </group>
          <group group_id="O2">
            <title>STAGE-II Group 2a: Placebo + CYD + CYD Booster (1 Year)</title>
            <description>Participants from Group 2 who received vaccination in STAGE-I and were seropositive at baseline received a booster injection of CYD dengue vaccine in STAGE-II at 1 year post last dose in STAGE-I (i.e., at Month 24).</description>
          </group>
          <group group_id="O3">
            <title>STAGE-II Group 3a: Placebo + CYD + CYD Booster (1 Year)</title>
            <description>Participants from Group 3 who received vaccination in STAGE-I and were seropositive at baseline received a booster injection of CYD dengue vaccine in STAGE-II at 1 year post last dose in STAGE-I (i.e., at Month 24).</description>
          </group>
          <group group_id="O4">
            <title>STAGE-II Group 1b: CYD Vaccine + CYD Booster Vaccine (2 Years)</title>
            <description>Participants from Group 1 who received vaccination in STAGE-I and were seropositive at baseline received a booster injection of CYD dengue vaccine in STAGE-II at 2 years post last dose in STAGE-I (i.e., at Month 36).</description>
          </group>
          <group group_id="O5">
            <title>STAGE-II Group 2b: Placebo + CYD + CYD Booster (2 Years)</title>
            <description>Participants from Group 2 who received vaccination in STAGE-I and were seropositive at baseline received a booster injection of CYD dengue vaccine in STAGE-II at 2 years post last dose in STAGE-I (i.e., at Month 36).</description>
          </group>
          <group group_id="O6">
            <title>STAGE-II Group 3b: Placebo + CYD + CYD Booster (2 Years)</title>
            <description>Participants from Group 3 who received vaccination in STAGE-I and were seropositive at baseline received a booster injection of CYD dengue vaccine in STAGE-II at 2 years post last dose in STAGE-I (i.e., at Month 36).</description>
          </group>
        </group_list>
        <measure>
          <title>STAGE-II: Percentage of Participants With Antibodies Titer &gt;=10 (1/Dilution) Against Each Serotype With the Parental Dengue Virus Strain in Participants Seropositive at Baseline</title>
          <description>GMTs of antibodies against each of the 4 dengue virus serotypes (1, 2, 3 or 4) were assessed using the PRNT assay method. Dengue seropositive participants at Baseline were defined as participants with titers &gt;=10 (1/dilution) for at least one serotype with the parental dengue virus strains.</description>
          <population>Analysis was performed on FAS. Here, 'Overall number of participant analyzed'=participants with available data for this outcome measure and 'Number analyzed'=participants with available data for each specified category.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="141"/>
                <count group_id="O2" value="144"/>
                <count group_id="O3" value="147"/>
                <count group_id="O4" value="140"/>
                <count group_id="O5" value="144"/>
                <count group_id="O6" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 1: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="141"/>
                    <count group_id="O2" value="144"/>
                    <count group_id="O3" value="147"/>
                    <count group_id="O4" value="140"/>
                    <count group_id="O5" value="144"/>
                    <count group_id="O6" value="144"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.2" lower_limit="86.5" upper_limit="96.0"/>
                    <measurement group_id="O2" value="90.3" lower_limit="84.2" upper_limit="94.6"/>
                    <measurement group_id="O3" value="91.8" lower_limit="86.2" upper_limit="95.7"/>
                    <measurement group_id="O4" value="92.1" lower_limit="86.4" upper_limit="96.0"/>
                    <measurement group_id="O5" value="91.7" lower_limit="85.9" upper_limit="95.6"/>
                    <measurement group_id="O6" value="97.2" lower_limit="93.0" upper_limit="99.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 1: 28 days post vaccination 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="137"/>
                    <count group_id="O2" value="140"/>
                    <count group_id="O3" value="145"/>
                    <count group_id="O4" value="137"/>
                    <count group_id="O5" value="142"/>
                    <count group_id="O6" value="140"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.3" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.3" lower_limit="96.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="97.5" upper_limit="100.0"/>
                    <measurement group_id="O4" value="99.3" lower_limit="96.0" upper_limit="100.0"/>
                    <measurement group_id="O5" value="99.3" lower_limit="96.1" upper_limit="100.0"/>
                    <measurement group_id="O6" value="100.0" lower_limit="97.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 1 : 1 year post vaccination 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="137"/>
                    <count group_id="O2" value="138"/>
                    <count group_id="O3" value="143"/>
                    <count group_id="O4" value="128"/>
                    <count group_id="O5" value="130"/>
                    <count group_id="O6" value="131"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.3" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.3" lower_limit="96.0" upper_limit="100.0"/>
                    <measurement group_id="O3" value="99.3" lower_limit="96.2" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100.0" lower_limit="97.2" upper_limit="100.0"/>
                    <measurement group_id="O5" value="96.9" lower_limit="92.3" upper_limit="99.2"/>
                    <measurement group_id="O6" value="98.5" lower_limit="94.6" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 2: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="141"/>
                    <count group_id="O2" value="144"/>
                    <count group_id="O3" value="147"/>
                    <count group_id="O4" value="140"/>
                    <count group_id="O5" value="144"/>
                    <count group_id="O6" value="144"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.3" lower_limit="96.1" upper_limit="100.0"/>
                    <measurement group_id="O2" value="94.4" lower_limit="89.3" upper_limit="97.6"/>
                    <measurement group_id="O3" value="94.6" lower_limit="89.6" upper_limit="97.6"/>
                    <measurement group_id="O4" value="96.4" lower_limit="91.9" upper_limit="98.8"/>
                    <measurement group_id="O5" value="94.4" lower_limit="89.3" upper_limit="97.6"/>
                    <measurement group_id="O6" value="97.2" lower_limit="93.0" upper_limit="99.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 2 : 28 days post vaccination 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="137"/>
                    <count group_id="O2" value="140"/>
                    <count group_id="O3" value="145"/>
                    <count group_id="O4" value="137"/>
                    <count group_id="O5" value="142"/>
                    <count group_id="O6" value="140"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.3" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.3" lower_limit="96.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="97.5" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100.0" lower_limit="97.3" upper_limit="100.0"/>
                    <measurement group_id="O5" value="99.3" lower_limit="96.1" upper_limit="100.0"/>
                    <measurement group_id="O6" value="100.0" lower_limit="97.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 2 : 1 year post vaccination 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="137"/>
                    <count group_id="O2" value="138"/>
                    <count group_id="O3" value="143"/>
                    <count group_id="O4" value="128"/>
                    <count group_id="O5" value="130"/>
                    <count group_id="O6" value="131"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.3" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.3" lower_limit="96.0" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="97.5" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100.0" lower_limit="97.2" upper_limit="100.0"/>
                    <measurement group_id="O5" value="98.5" lower_limit="94.6" upper_limit="99.8"/>
                    <measurement group_id="O6" value="100.0" lower_limit="97.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="141"/>
                    <count group_id="O2" value="144"/>
                    <count group_id="O3" value="147"/>
                    <count group_id="O4" value="140"/>
                    <count group_id="O5" value="144"/>
                    <count group_id="O6" value="144"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.6" lower_limit="95.0" upper_limit="99.8"/>
                    <measurement group_id="O2" value="96.5" lower_limit="92.1" upper_limit="98.9"/>
                    <measurement group_id="O3" value="95.2" lower_limit="90.4" upper_limit="98.1"/>
                    <measurement group_id="O4" value="97.1" lower_limit="92.8" upper_limit="99.2"/>
                    <measurement group_id="O5" value="93.1" lower_limit="87.6" upper_limit="96.6"/>
                    <measurement group_id="O6" value="100.0" lower_limit="97.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3: 28 days post vaccination</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="137"/>
                    <count group_id="O2" value="140"/>
                    <count group_id="O3" value="145"/>
                    <count group_id="O4" value="137"/>
                    <count group_id="O5" value="142"/>
                    <count group_id="O6" value="140"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.3" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="97.4" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="97.5" upper_limit="100.0"/>
                    <measurement group_id="O4" value="99.3" lower_limit="96.0" upper_limit="100.0"/>
                    <measurement group_id="O5" value="100.0" lower_limit="97.4" upper_limit="100.0"/>
                    <measurement group_id="O6" value="100.0" lower_limit="97.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 3 : 1 year post vaccination 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="137"/>
                    <count group_id="O2" value="138"/>
                    <count group_id="O3" value="143"/>
                    <count group_id="O4" value="128"/>
                    <count group_id="O5" value="130"/>
                    <count group_id="O6" value="131"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.3" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.3" lower_limit="96.0" upper_limit="100.0"/>
                    <measurement group_id="O3" value="99.3" lower_limit="96.2" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100.0" lower_limit="97.2" upper_limit="100.0"/>
                    <measurement group_id="O5" value="100.0" lower_limit="97.2" upper_limit="100.0"/>
                    <measurement group_id="O6" value="100.0" lower_limit="97.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4: Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="141"/>
                    <count group_id="O2" value="144"/>
                    <count group_id="O3" value="147"/>
                    <count group_id="O4" value="140"/>
                    <count group_id="O5" value="144"/>
                    <count group_id="O6" value="144"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.6" lower_limit="88.2" upper_limit="97.0"/>
                    <measurement group_id="O2" value="93.1" lower_limit="87.6" upper_limit="96.6"/>
                    <measurement group_id="O3" value="89.8" lower_limit="83.7" upper_limit="94.2"/>
                    <measurement group_id="O4" value="95.0" lower_limit="90.0" upper_limit="98.0"/>
                    <measurement group_id="O5" value="91.7" lower_limit="85.9" upper_limit="95.6"/>
                    <measurement group_id="O6" value="94.4" lower_limit="89.3" upper_limit="97.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4: 28 days post vaccination 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="137"/>
                    <count group_id="O2" value="140"/>
                    <count group_id="O3" value="145"/>
                    <count group_id="O4" value="137"/>
                    <count group_id="O5" value="142"/>
                    <count group_id="O6" value="140"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.3" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="97.4" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="97.5" upper_limit="100.0"/>
                    <measurement group_id="O4" value="100.0" lower_limit="97.3" upper_limit="100.0"/>
                    <measurement group_id="O5" value="100.0" lower_limit="97.4" upper_limit="100.0"/>
                    <measurement group_id="O6" value="100.0" lower_limit="97.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4: 1 year post vaccination 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="137"/>
                    <count group_id="O2" value="138"/>
                    <count group_id="O3" value="143"/>
                    <count group_id="O4" value="128"/>
                    <count group_id="O5" value="130"/>
                    <count group_id="O6" value="131"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="97.3" upper_limit="100.0"/>
                    <measurement group_id="O2" value="99.3" lower_limit="96.0" upper_limit="100.0"/>
                    <measurement group_id="O3" value="98.6" lower_limit="95.0" upper_limit="99.8"/>
                    <measurement group_id="O4" value="100.0" lower_limit="97.2" upper_limit="100.0"/>
                    <measurement group_id="O5" value="98.5" lower_limit="94.6" upper_limit="99.8"/>
                    <measurement group_id="O6" value="100.0" lower_limit="97.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>STAGE-I: Number of Participants With Immediate Unsolicited Adverse Events Following Vaccination With CYD Dengue Vaccine or Placebo (Post Any Vaccination)</title>
        <description>An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the electronic case report form (eCRF) in terms of diagnosis and/or onset post-vaccination. Immediate unsolicited AE were AEs that occurred within 30 minutes after any vaccination.</description>
        <time_frame>Within 30 minutes after any vaccination (1, 2, or 3)</time_frame>
        <population>Analysis was performed on safety analysis set (SafAS) that included participants who had received at least one injection of either CYD dengue vaccine or placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>STAGE-I Group 1: CYD Dengue Vaccine</title>
            <description>Participants received 3 doses of CYD dengue vaccine 0.5 mL SC at Day 0 (Vaccination 1), Month 6 (Vaccination 2), and Month 12 (Vaccination 3).</description>
          </group>
          <group group_id="O2">
            <title>STAGE-I Group 2: Placebo + CYD Dengue Vaccine (Months 6,12)</title>
            <description>Participants received a dose of placebo at Day 0 (Vaccination 1) along with 2 doses of CYD dengue vaccine 0.5 mL SC at Month 6 (Vaccination 2) and Month 12 (Vaccination 3).</description>
          </group>
          <group group_id="O3">
            <title>STAGE-I Group 3: Placebo + CYD Dengue Vaccine (Month 12)</title>
            <description>Participants received 2 doses of placebo at Day 0 (Vaccination 1) and Month 6 (Vaccination 2) along with a dose of CYD dengue vaccine 0.5 mL SC at Month 12 (Vaccination 3).</description>
          </group>
        </group_list>
        <measure>
          <title>STAGE-I: Number of Participants With Immediate Unsolicited Adverse Events Following Vaccination With CYD Dengue Vaccine or Placebo (Post Any Vaccination)</title>
          <description>An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the electronic case report form (eCRF) in terms of diagnosis and/or onset post-vaccination. Immediate unsolicited AE were AEs that occurred within 30 minutes after any vaccination.</description>
          <population>Analysis was performed on safety analysis set (SafAS) that included participants who had received at least one injection of either CYD dengue vaccine or placebo.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="348"/>
                <count group_id="O2" value="348"/>
                <count group_id="O3" value="352"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>STAGE-II: Number of Participants With Immediate Unsolicited Adverse Events Following Booster Vaccination With CYD Dengue Vaccine</title>
        <description>An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the eCRF in terms of diagnosis and / or onset post-vaccination. Immediate unsolicited AE were AEs that occurred within 30 minutes after vaccination.</description>
        <time_frame>Within 30 minutes after CYD booster vaccination</time_frame>
        <population>Analysis was performed on SafAS.</population>
        <group_list>
          <group group_id="O1">
            <title>STAGE-II Group 1a: CYD Vaccine + CYD Booster Vaccine (1 Year)</title>
            <description>Participants from Group 1 who received vaccination in STAGE-I; and were seropositive at Baseline received a booster dose of CYD dengue vaccine in STAGE-II at 1 year post last dose in STAGE-I (i.e., at Month 24).</description>
          </group>
          <group group_id="O2">
            <title>STAGE-II Group 2a: Placebo + CYD + CYD Booster (1 Year)</title>
            <description>Participants from Group 2 who received vaccination in STAGE-I and were seropositive at baseline received a booster injection of CYD dengue vaccine in STAGE-II at 1 year post last dose in STAGE-I (i.e., at Month 24).</description>
          </group>
          <group group_id="O3">
            <title>STAGE-II Group 3a: Placebo + CYD + CYD Booster (1 Year)</title>
            <description>Participants from Group 3 who received vaccination in STAGE-I and were seropositive at baseline received a booster injection of CYD dengue vaccine in STAGE-II at 1 year post last dose in STAGE-I (i.e., at Month 24).</description>
          </group>
          <group group_id="O4">
            <title>STAGE-II Group 1b: CYD Vaccine + CYD Booster Vaccine (2 Years)</title>
            <description>Participants from Group 1 who received vaccination in STAGE-I and were seropositive at baseline received a booster injection of CYD dengue vaccine in STAGE-II at 2 years post last dose in STAGE-I (i.e., at Month 36).</description>
          </group>
          <group group_id="O5">
            <title>STAGE-II Group 2b: Placebo + CYD + CYD Booster (2 Years)</title>
            <description>Participants from Group 2 who received vaccination in STAGE-I and were seropositive at baseline received a booster injection of CYD dengue vaccine in STAGE-II at 2 years post last dose in STAGE-I (i.e., at Month 36).</description>
          </group>
          <group group_id="O6">
            <title>STAGE-II Group 3b: Placebo + CYD + CYD Booster (2 Years)</title>
            <description>Participants from Group 3 who received vaccination in STAGE-I and were seropositive at baseline received a booster injection of CYD dengue vaccine in STAGE-II at 2 years post last dose in STAGE-I (i.e., at Month 36).</description>
          </group>
        </group_list>
        <measure>
          <title>STAGE-II: Number of Participants With Immediate Unsolicited Adverse Events Following Booster Vaccination With CYD Dengue Vaccine</title>
          <description>An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the eCRF in terms of diagnosis and / or onset post-vaccination. Immediate unsolicited AE were AEs that occurred within 30 minutes after vaccination.</description>
          <population>Analysis was performed on SafAS.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="53"/>
                <count group_id="O5" value="56"/>
                <count group_id="O6" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>STAGE-I: Number of Participants With Solicited Injection Site Reactions Following Vaccination With CYD Dengue Vaccine or Placebo (Post Any Vaccination)</title>
        <description>Adverse reaction (AR) was defined as all noxious and unintended responses to a medicinal product related to any dose. A Solicited Reaction (SR) was defined as an AR observed and reported under the conditions (symptom and onset) prelisted (i.e., solicited) in the eCRF and considered as related to vaccination. Solicited injection site reaction was an AR at and around the injection site that included pain, erythema, and swelling.</description>
        <time_frame>Within 7 days after any vaccination (1, 2, or 3)</time_frame>
        <population>Analysis was performed on SafAS. Here, 'Number analyzed'=participants with available data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>STAGE-I Group 1: CYD Dengue Vaccine</title>
            <description>Participants received 3 doses of CYD dengue vaccine 0.5 mL SC at Day 0 (Vaccination 1), Month 6 (Vaccination 2), and Month 12 (Vaccination 3).</description>
          </group>
          <group group_id="O2">
            <title>STAGE-I Group 2: Placebo + CYD Dengue Vaccine (Months 6,12)</title>
            <description>Participants received a dose of placebo at Day 0 (Vaccination 1) along with 2 doses of CYD dengue vaccine 0.5 mL SC at Month 6 (Vaccination 2) and Month 12 (Vaccination 3).</description>
          </group>
          <group group_id="O3">
            <title>STAGE-I Group 3: Placebo + CYD Dengue Vaccine (Month 12)</title>
            <description>Participants received 2 doses of placebo at Day 0 (Vaccination 1) and Month 6 (Vaccination 2) along with a dose of CYD dengue vaccine 0.5 mL SC at Month 12 (Vaccination 3).</description>
          </group>
        </group_list>
        <measure>
          <title>STAGE-I: Number of Participants With Solicited Injection Site Reactions Following Vaccination With CYD Dengue Vaccine or Placebo (Post Any Vaccination)</title>
          <description>Adverse reaction (AR) was defined as all noxious and unintended responses to a medicinal product related to any dose. A Solicited Reaction (SR) was defined as an AR observed and reported under the conditions (symptom and onset) prelisted (i.e., solicited) in the eCRF and considered as related to vaccination. Solicited injection site reaction was an AR at and around the injection site that included pain, erythema, and swelling.</description>
          <population>Analysis was performed on SafAS. Here, 'Number analyzed'=participants with available data for each specified category.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="347"/>
                <count group_id="O2" value="347"/>
                <count group_id="O3" value="352"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109"/>
                    <measurement group_id="O2" value="114"/>
                    <measurement group_id="O3" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>STAGE-I: Number of Participants With Solicited Injection Site Reactions Following Vaccination With CYD Dengue Vaccine or Placebo (Post Each Vaccination)</title>
        <description>AR was defined as all noxious and unintended responses to a medicinal product related to any dose. An SR was defined as an AR observed and reported under the conditions (symptom and onset) prelisted (i.e., solicited) in the eCRF and considered as related to vaccination. Solicited injection site reaction was an AR at and around the injection site that included pain, erythema, and swelling.</description>
        <time_frame>Within 7 days after each vaccination (1, 2, and 3)</time_frame>
        <population>Analysis was performed on SafAS. Here, 'Number analyzed'=participants with available data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>STAGE-I Group 1: CYD Dengue Vaccine</title>
            <description>Participants received 3 doses of CYD dengue vaccine 0.5 mL SC at Day 0 (Vaccination 1), Month 6 (Vaccination 2), and Month 12 (Vaccination 3).</description>
          </group>
          <group group_id="O2">
            <title>STAGE-I Group 2: Placebo + CYD Dengue Vaccine (Months 6,12)</title>
            <description>Participants received a dose of placebo at Day 0 (Vaccination 1) along with 2 doses of CYD dengue vaccine 0.5 mL SC at Month 6 (Vaccination 2) and Month 12 (Vaccination 3).</description>
          </group>
          <group group_id="O3">
            <title>STAGE-I Group 3: Placebo + CYD Dengue Vaccine (Month 12)</title>
            <description>Participants received 2 doses of placebo at Day 0 (Vaccination 1) and Month 6 (Vaccination 2) along with a dose of CYD dengue vaccine 0.5 mL SC at Month 12 (Vaccination 3).</description>
          </group>
        </group_list>
        <measure>
          <title>STAGE-I: Number of Participants With Solicited Injection Site Reactions Following Vaccination With CYD Dengue Vaccine or Placebo (Post Each Vaccination)</title>
          <description>AR was defined as all noxious and unintended responses to a medicinal product related to any dose. An SR was defined as an AR observed and reported under the conditions (symptom and onset) prelisted (i.e., solicited) in the eCRF and considered as related to vaccination. Solicited injection site reaction was an AR at and around the injection site that included pain, erythema, and swelling.</description>
          <population>Analysis was performed on SafAS. Here, 'Number analyzed'=participants with available data for each specified category.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="347"/>
                <count group_id="O2" value="347"/>
                <count group_id="O3" value="352"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Post-vaccination 1: Pain</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="347"/>
                    <count group_id="O2" value="347"/>
                    <count group_id="O3" value="352"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="61"/>
                    <measurement group_id="O3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-vaccination 1: Erythema</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="347"/>
                    <count group_id="O2" value="347"/>
                    <count group_id="O3" value="352"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post vaccination 1: Swelling</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="347"/>
                    <count group_id="O2" value="347"/>
                    <count group_id="O3" value="352"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-vaccination 2: Pain</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="332"/>
                    <count group_id="O2" value="328"/>
                    <count group_id="O3" value="332"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="53"/>
                    <measurement group_id="O3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-vaccination 2: Erythema</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="332"/>
                    <count group_id="O2" value="328"/>
                    <count group_id="O3" value="332"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-vaccination 2: Swelling</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="332"/>
                    <count group_id="O2" value="328"/>
                    <count group_id="O3" value="332"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-vaccination 3: Pain</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="325"/>
                    <count group_id="O2" value="321"/>
                    <count group_id="O3" value="324"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="49"/>
                    <measurement group_id="O3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-vaccination 3: Erythema</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="325"/>
                    <count group_id="O2" value="321"/>
                    <count group_id="O3" value="324"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-vaccination 3: Swelling</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="325"/>
                    <count group_id="O2" value="321"/>
                    <count group_id="O3" value="324"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>STAGE-I: Number of Participants With Solicited Systemic Reactions Following Vaccination With CYD Dengue Vaccine or Placebo (Post Any Vaccination)</title>
        <description>An AR was defined as all noxious and unintended responses to a medicinal product related to any dose. An SR was defined as an AR observed and reported under the conditions (symptom and onset) prelisted (i.e., solicited) in the eCRF and considered as related to vaccination. Systemic AEs were all AEs that were not injection site reactions. Solicited systemic reactions included fever, headache, malaise, myalgia, and asthenia.</description>
        <time_frame>Within 14 days after any vaccination (1, 2, or 3)</time_frame>
        <population>Analysis was performed on SafAS. Here, 'Number analyzed'=participants with available data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>STAGE-I Group 1: CYD Dengue Vaccine</title>
            <description>Participants received 3 doses of CYD dengue vaccine 0.5 mL SC at Day 0 (Vaccination 1), Month 6 (Vaccination 2), and Month 12 (Vaccination 3).</description>
          </group>
          <group group_id="O2">
            <title>STAGE-I Group 2: Placebo + CYD Dengue Vaccine (Months 6,12)</title>
            <description>Participants received a dose of placebo at Day 0 (Vaccination 1) along with 2 doses of CYD dengue vaccine 0.5 mL SC at Month 6 (Vaccination 2) and Month 12 (Vaccination 3).</description>
          </group>
          <group group_id="O3">
            <title>STAGE-I Group 3: Placebo + CYD Dengue Vaccine (Month 12)</title>
            <description>Participants received 2 doses of placebo at Day 0 (Vaccination 1) and Month 6 (Vaccination 2) along with a dose of CYD dengue vaccine 0.5 mL SC at Month 12 (Vaccination 3).</description>
          </group>
        </group_list>
        <measure>
          <title>STAGE-I: Number of Participants With Solicited Systemic Reactions Following Vaccination With CYD Dengue Vaccine or Placebo (Post Any Vaccination)</title>
          <description>An AR was defined as all noxious and unintended responses to a medicinal product related to any dose. An SR was defined as an AR observed and reported under the conditions (symptom and onset) prelisted (i.e., solicited) in the eCRF and considered as related to vaccination. Systemic AEs were all AEs that were not injection site reactions. Solicited systemic reactions included fever, headache, malaise, myalgia, and asthenia.</description>
          <population>Analysis was performed on SafAS. Here, 'Number analyzed'=participants with available data for each specified category.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="347"/>
                <count group_id="O2" value="347"/>
                <count group_id="O3" value="352"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129"/>
                    <measurement group_id="O2" value="122"/>
                    <measurement group_id="O3" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114"/>
                    <measurement group_id="O2" value="98"/>
                    <measurement group_id="O3" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110"/>
                    <measurement group_id="O2" value="92"/>
                    <measurement group_id="O3" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asthenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                    <measurement group_id="O2" value="80"/>
                    <measurement group_id="O3" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>STAGE-I: Number of Participants With Solicited Systemic Reactions Following Vaccination With CYD Dengue Vaccine or Placebo (Post Each Vaccination)</title>
        <description>An AR was defined as all noxious and unintended responses to a medicinal product related to any dose. A SR was defined as an AR observed and reported under the conditions (symptom and onset) prelisted (i.e., solicited) in the eCRF and considered as related to vaccination. Solicited systemic reactions included fever, headache, malaise, myalgia, and asthenia.</description>
        <time_frame>Within 14 days after each vaccination (1, 2, and 3)</time_frame>
        <population>Analysis was performed on SafAS. Here, 'Number analyzed'=participants with available data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>STAGE-I Group 1: CYD Dengue Vaccine</title>
            <description>Participants received 3 doses of CYD dengue vaccine 0.5 mL SC at Day 0 (Vaccination 1), Month 6 (Vaccination 2), and Month 12 (Vaccination 3).</description>
          </group>
          <group group_id="O2">
            <title>STAGE-I Group 2: Placebo + CYD Dengue Vaccine (Months 6,12)</title>
            <description>Participants received a dose of placebo at Day 0 (Vaccination 1) along with 2 doses of CYD dengue vaccine 0.5 mL SC at Month 6 (Vaccination 2) and Month 12 (Vaccination 3).</description>
          </group>
          <group group_id="O3">
            <title>STAGE-I Group 3: Placebo + CYD Dengue Vaccine (Month 12)</title>
            <description>Participants received 2 doses of placebo at Day 0 (Vaccination 1) and Month 6 (Vaccination 2) along with a dose of CYD dengue vaccine 0.5 mL SC at Month 12 (Vaccination 3).</description>
          </group>
        </group_list>
        <measure>
          <title>STAGE-I: Number of Participants With Solicited Systemic Reactions Following Vaccination With CYD Dengue Vaccine or Placebo (Post Each Vaccination)</title>
          <description>An AR was defined as all noxious and unintended responses to a medicinal product related to any dose. A SR was defined as an AR observed and reported under the conditions (symptom and onset) prelisted (i.e., solicited) in the eCRF and considered as related to vaccination. Solicited systemic reactions included fever, headache, malaise, myalgia, and asthenia.</description>
          <population>Analysis was performed on SafAS. Here, 'Number analyzed'=participants with available data for each specified category.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="347"/>
                <count group_id="O2" value="347"/>
                <count group_id="O3" value="352"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Post-vaccination 1: Fever</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="347"/>
                    <count group_id="O2" value="347"/>
                    <count group_id="O3" value="352"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-vaccination 1: Headache</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="347"/>
                    <count group_id="O2" value="347"/>
                    <count group_id="O3" value="352"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="83"/>
                    <measurement group_id="O3" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-vaccination 1: Malaise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="347"/>
                    <count group_id="O2" value="347"/>
                    <count group_id="O3" value="352"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="60"/>
                    <measurement group_id="O3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-vaccination 1: Myalgia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="347"/>
                    <count group_id="O2" value="347"/>
                    <count group_id="O3" value="352"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="55"/>
                    <measurement group_id="O3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-vaccination 1: Asthenia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="347"/>
                    <count group_id="O2" value="347"/>
                    <count group_id="O3" value="352"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63"/>
                    <measurement group_id="O2" value="52"/>
                    <measurement group_id="O3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-vaccination 2: Fever</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="332"/>
                    <count group_id="O2" value="327"/>
                    <count group_id="O3" value="330"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-vaccination 2: Headache</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="332"/>
                    <count group_id="O2" value="328"/>
                    <count group_id="O3" value="332"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="55"/>
                    <measurement group_id="O3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-vaccination 2: Malaise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="332"/>
                    <count group_id="O2" value="328"/>
                    <count group_id="O3" value="332"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-vaccination 2: Myalgia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="332"/>
                    <count group_id="O2" value="328"/>
                    <count group_id="O3" value="332"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-vaccination 2: Asthenia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="332"/>
                    <count group_id="O2" value="328"/>
                    <count group_id="O3" value="332"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-vaccination 3: Fever</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="324"/>
                    <count group_id="O2" value="317"/>
                    <count group_id="O3" value="317"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-vaccination 3: Headache</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="325"/>
                    <count group_id="O2" value="321"/>
                    <count group_id="O3" value="324"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-vaccination 3: Malaise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="325"/>
                    <count group_id="O2" value="321"/>
                    <count group_id="O3" value="324"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-vaccination 3: Myalgia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="325"/>
                    <count group_id="O2" value="321"/>
                    <count group_id="O3" value="324"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-vaccination 3: Asthenia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="325"/>
                    <count group_id="O2" value="321"/>
                    <count group_id="O3" value="324"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>STAGE-II: Number of Participants With Solicited Injection Site Reactions Following Booster Vaccination With CYD Dengue Vaccine</title>
        <description>An AR was defined as all noxious and unintended responses to a medicinal product related to any dose. A SR was defined as an AR observed and reported under the conditions (symptom and onset) prelisted (i.e., solicited) in the eCRF and considered as related to vaccination. Solicited injection site reaction was an AR at and around the injection site that included pain, erythema, and swelling.</description>
        <time_frame>Within 7 days after CYD booster vaccination</time_frame>
        <population>Analysis was performed on SafAS. Here, 'Number analyzed'=participants with available data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>STAGE-II Group 1a: CYD Vaccine + CYD Booster Vaccine (1 Year)</title>
            <description>Participants from Group 1 who received vaccination in STAGE-I; and were seropositive at Baseline received a booster dose of CYD dengue vaccine in STAGE-II at 1 year post last dose in STAGE-I (i.e., at Month 24).</description>
          </group>
          <group group_id="O2">
            <title>STAGE-II Group 2a: Placebo + CYD + CYD Booster (1 Year)</title>
            <description>Participants from Group 2 who received vaccination in STAGE-I and were seropositive at baseline received a booster injection of CYD dengue vaccine in STAGE-II at 1 year post last dose in STAGE-I (i.e., at Month 24).</description>
          </group>
          <group group_id="O3">
            <title>STAGE-II Group 3a: Placebo + CYD + CYD Booster (1 Year)</title>
            <description>Participants from Group 3 who received vaccination in STAGE-I and were seropositive at baseline received a booster injection of CYD dengue vaccine in STAGE-II at 1 year post last dose in STAGE-I (i.e., at Month 24).</description>
          </group>
          <group group_id="O4">
            <title>STAGE-II Group 1b: CYD Vaccine + CYD Booster Vaccine (2 Years)</title>
            <description>Participants from Group 1 who received vaccination in STAGE-I and were seropositive at baseline received a booster injection of CYD dengue vaccine in STAGE-II at 2 years post last dose in STAGE-I (i.e., at Month 36).</description>
          </group>
          <group group_id="O5">
            <title>STAGE-II Group 2b: Placebo + CYD + CYD Booster (2 Years)</title>
            <description>Participants from Group 2 who received vaccination in STAGE-I and were seropositive at baseline received a booster injection of CYD dengue vaccine in STAGE-II at 2 years post last dose in STAGE-I (i.e., at Month 36).</description>
          </group>
          <group group_id="O6">
            <title>STAGE-II Group 3b: Placebo + CYD + CYD Booster (2 Years)</title>
            <description>Participants from Group 3 who received vaccination in STAGE-I and were seropositive at baseline received a booster injection of CYD dengue vaccine in STAGE-II at 2 years post last dose in STAGE-I (i.e., at Month 36).</description>
          </group>
        </group_list>
        <measure>
          <title>STAGE-II: Number of Participants With Solicited Injection Site Reactions Following Booster Vaccination With CYD Dengue Vaccine</title>
          <description>An AR was defined as all noxious and unintended responses to a medicinal product related to any dose. A SR was defined as an AR observed and reported under the conditions (symptom and onset) prelisted (i.e., solicited) in the eCRF and considered as related to vaccination. Solicited injection site reaction was an AR at and around the injection site that included pain, erythema, and swelling.</description>
          <population>Analysis was performed on SafAS. Here, 'Number analyzed'=participants with available data for each specified category.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="53"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="12"/>
                    <measurement group_id="O6" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>STAGE-II: Number of Participants With Solicited Systemic Reactions Following Booster Vaccination With CYD Dengue Vaccine</title>
        <description>An AR was defined as all noxious and unintended responses to a medicinal product related to any dose. A SR was defined as an AR observed and reported under the conditions (symptom and onset) prelisted (i.e., solicited) in the eCRF and considered as related to vaccination. Solicited systemic reactions included fever, headache, malaise, myalgia, and asthenia.</description>
        <time_frame>Within 14 days after CYD booster vaccination</time_frame>
        <population>Analysis was performed on SafAS. Here, 'Number analyzed'=participants with available data for each specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>STAGE-II Group 1a: CYD Vaccine + CYD Booster Vaccine (1 Year)</title>
            <description>Participants from Group 1 who received vaccination in STAGE-I; and were seropositive at Baseline received a booster dose of CYD dengue vaccine in STAGE-II at 1 year post last dose in STAGE-I (i.e., at Month 24).</description>
          </group>
          <group group_id="O2">
            <title>STAGE-II Group 2a: Placebo + CYD + CYD Booster (1 Year)</title>
            <description>Participants from Group 2 who received vaccination in STAGE-I and were seropositive at baseline received a booster injection of CYD dengue vaccine in STAGE-II at 1 year post last dose in STAGE-I (i.e., at Month 24).</description>
          </group>
          <group group_id="O3">
            <title>STAGE-II Group 3a: Placebo + CYD + CYD Booster (1 Year)</title>
            <description>Participants from Group 3 who received vaccination in STAGE-I and were seropositive at baseline received a booster injection of CYD dengue vaccine in STAGE-II at 1 year post last dose in STAGE-I (i.e., at Month 24).</description>
          </group>
          <group group_id="O4">
            <title>STAGE-II Group 1b: CYD Vaccine + CYD Booster Vaccine (2 Years)</title>
            <description>Participants from Group 1 who received vaccination in STAGE-I and were seropositive at baseline received a booster injection of CYD dengue vaccine in STAGE-II at 2 years post last dose in STAGE-I (i.e., at Month 36).</description>
          </group>
          <group group_id="O5">
            <title>STAGE-II Group 2b: Placebo + CYD + CYD Booster (2 Years)</title>
            <description>Participants from Group 2 who received vaccination in STAGE-I and were seropositive at baseline received a booster injection of CYD dengue vaccine in STAGE-II at 2 years post last dose in STAGE-I (i.e., at Month 36).</description>
          </group>
          <group group_id="O6">
            <title>STAGE-II Group 3b: Placebo + CYD + CYD Booster (2 Years)</title>
            <description>Participants from Group 3 who received vaccination in STAGE-I and were seropositive at baseline received a booster injection of CYD dengue vaccine in STAGE-II at 2 years post last dose in STAGE-I (i.e., at Month 36).</description>
          </group>
        </group_list>
        <measure>
          <title>STAGE-II: Number of Participants With Solicited Systemic Reactions Following Booster Vaccination With CYD Dengue Vaccine</title>
          <description>An AR was defined as all noxious and unintended responses to a medicinal product related to any dose. A SR was defined as an AR observed and reported under the conditions (symptom and onset) prelisted (i.e., solicited) in the eCRF and considered as related to vaccination. Solicited systemic reactions included fever, headache, malaise, myalgia, and asthenia.</description>
          <population>Analysis was performed on SafAS. Here, 'Number analyzed'=participants with available data for each specified category.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="53"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="59"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="53"/>
                    <count group_id="O5" value="54"/>
                    <count group_id="O6" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="59"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="53"/>
                    <count group_id="O5" value="54"/>
                    <count group_id="O6" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaise</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="59"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="53"/>
                    <count group_id="O5" value="54"/>
                    <count group_id="O6" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="59"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="53"/>
                    <count group_id="O5" value="54"/>
                    <count group_id="O6" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="12"/>
                    <measurement group_id="O6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asthenia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="59"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="53"/>
                    <count group_id="O5" value="54"/>
                    <count group_id="O6" value="52"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>STAGE-I: Number of Participants Reporting Unsolicited Adverse Events Following Vaccination With CYD Dengue Vaccine or Placebo</title>
        <description>An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the eCRF in terms of diagnosis and/or onset post-vaccination.</description>
        <time_frame>Within 28 days after any vaccination (1, 2, or 3)</time_frame>
        <population>Analysis was performed on SafAS.</population>
        <group_list>
          <group group_id="O1">
            <title>STAGE-I Group 1: CYD Dengue Vaccine</title>
            <description>Participants received 3 doses of CYD dengue vaccine 0.5 mL SC at Day 0 (Vaccination 1), Month 6 (Vaccination 2), and Month 12 (Vaccination 3).</description>
          </group>
          <group group_id="O2">
            <title>STAGE-I Group 2: Placebo + CYD Dengue Vaccine (Months 6,12)</title>
            <description>Participants received a dose of placebo at Day 0 (Vaccination 1) along with 2 doses of CYD dengue vaccine 0.5 mL SC at Month 6 (Vaccination 2) and Month 12 (Vaccination 3).</description>
          </group>
          <group group_id="O3">
            <title>STAGE-I Group 3: Placebo + CYD Dengue Vaccine (Month 12)</title>
            <description>Participants received 2 doses of placebo at Day 0 (Vaccination 1) and Month 6 (Vaccination 2) along with a dose of CYD dengue vaccine 0.5 mL SC at Month 12 (Vaccination 3).</description>
          </group>
        </group_list>
        <measure>
          <title>STAGE-I: Number of Participants Reporting Unsolicited Adverse Events Following Vaccination With CYD Dengue Vaccine or Placebo</title>
          <description>An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the eCRF in terms of diagnosis and/or onset post-vaccination.</description>
          <population>Analysis was performed on SafAS.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="348"/>
                <count group_id="O2" value="348"/>
                <count group_id="O3" value="352"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="94"/>
                    <measurement group_id="O3" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>STAGE-II: Number of Participants Reporting Unsolicited Adverse Events Following Booster Vaccination With CYD Dengue Vaccine</title>
        <description>An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An unsolicited AE was an observed AE that does not fulfill the conditions prelisted in the eCRF in terms of diagnosis and/or onset post-vaccination.</description>
        <time_frame>Within 28 days after CYD booster Vaccination</time_frame>
        <population>Analysis was performed on SafAS.</population>
        <group_list>
          <group group_id="O1">
            <title>STAGE-II Group 1a: CYD Vaccine + CYD Booster Vaccine (1 Year)</title>
            <description>Participants from Group 1 who received vaccination in STAGE-I; and were seropositive at Baseline received a booster dose of CYD dengue vaccine in STAGE-II at 1 year post last dose in STAGE-I (i.e., at Month 24).</description>
          </group>
          <group group_id="O2">
            <title>STAGE-II Group 2a: Placebo + CYD + CYD Booster (1 Year)</title>
            <description>Participants from Group 2 who received vaccination in STAGE-I and were seropositive at baseline received a booster injection of CYD dengue vaccine in STAGE-II at 1 year post last dose in STAGE-I (i.e., at Month 24).</description>
          </group>
          <group group_id="O3">
            <title>STAGE-II Group 3a: Placebo + CYD + CYD Booster (1 Year)</title>
            <description>Participants from Group 3 who received vaccination in STAGE-I and were seropositive at baseline received a booster injection of CYD dengue vaccine in STAGE-II at 1 year post last dose in STAGE-I (i.e., at Month 24).</description>
          </group>
          <group group_id="O4">
            <title>STAGE-II Group 1b: CYD Vaccine + CYD Booster Vaccine (2 Years)</title>
            <description>Participants from Group 1 who received vaccination in STAGE-I and were seropositive at baseline received a booster injection of CYD dengue vaccine in STAGE-II at 2 years post last dose in STAGE-I (i.e., at Month 36).</description>
          </group>
          <group group_id="O5">
            <title>STAGE-II Group 2b: Placebo + CYD + CYD Booster (2 Years)</title>
            <description>Participants from Group 2 who received vaccination in STAGE-I and were seropositive at baseline received a booster injection of CYD dengue vaccine in STAGE-II at 2 years post last dose in STAGE-I (i.e., at Month 36).</description>
          </group>
          <group group_id="O6">
            <title>STAGE-II Group 3b: Placebo + CYD + CYD Booster (2 Years)</title>
            <description>Participants from Group 3 who received vaccination in STAGE-I and were seropositive at baseline received a booster injection of CYD dengue vaccine in STAGE-II at 2 years post last dose in STAGE-I (i.e., at Month 36).</description>
          </group>
        </group_list>
        <measure>
          <title>STAGE-II: Number of Participants Reporting Unsolicited Adverse Events Following Booster Vaccination With CYD Dengue Vaccine</title>
          <description>An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An unsolicited AE was an observed AE that does not fulfill the conditions prelisted in the eCRF in terms of diagnosis and/or onset post-vaccination.</description>
          <population>Analysis was performed on SafAS.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="53"/>
                <count group_id="O5" value="56"/>
                <count group_id="O6" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>STAGE-I: Number of Participants Reporting Serious Adverse Events Including Serious Adverse Event of Special Interests (AESI) Following Vaccination With CYD Dengue Vaccine or Placebo</title>
        <description>An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE was any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was congenital anomaly/birth defect, or was an important medical event. AESI were AEs that were considered by the Sponsor to be relevant for the monitoring of the safety profile of the investigational vaccine.</description>
        <time_frame>From Day 0 (post vaccination) up to 12 months after last vaccination in STAGE-I (i.e., up to 24 months)</time_frame>
        <population>Analysis was performed on SafAS.</population>
        <group_list>
          <group group_id="O1">
            <title>STAGE-I Group 1: CYD Dengue Vaccine</title>
            <description>Participants received 3 doses of CYD dengue vaccine 0.5 mL SC at Day 0 (Vaccination 1), Month 6 (Vaccination 2), and Month 12 (Vaccination 3).</description>
          </group>
          <group group_id="O2">
            <title>STAGE-I Group 2: Placebo + CYD Dengue Vaccine (Months 6,12)</title>
            <description>Participants received a dose of placebo at Day 0 (Vaccination 1) along with 2 doses of CYD dengue vaccine 0.5 mL SC at Month 6 (Vaccination 2) and Month 12 (Vaccination 3).</description>
          </group>
          <group group_id="O3">
            <title>STAGE-I Group 3: Placebo + CYD Dengue Vaccine (Month 12)</title>
            <description>Participants received 2 doses of placebo at Day 0 (Vaccination 1) and Month 6 (Vaccination 2) along with a dose of CYD dengue vaccine 0.5 mL SC at Month 12 (Vaccination 3).</description>
          </group>
        </group_list>
        <measure>
          <title>STAGE-I: Number of Participants Reporting Serious Adverse Events Including Serious Adverse Event of Special Interests (AESI) Following Vaccination With CYD Dengue Vaccine or Placebo</title>
          <description>An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE was any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was congenital anomaly/birth defect, or was an important medical event. AESI were AEs that were considered by the Sponsor to be relevant for the monitoring of the safety profile of the investigational vaccine.</description>
          <population>Analysis was performed on SafAS.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="348"/>
                <count group_id="O2" value="348"/>
                <count group_id="O3" value="352"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious AESI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>STAGE-II: Number of Participants Reporting Serious Adverse Events Including Serious Adverse Events Special Interest Following Booster Vaccination With CYD Dengue Vaccine</title>
        <description>An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE was any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was congenital anomaly/birth defect, or was an important medical event. AESI were AEs that were considered by the Sponsor to be relevant for the monitoring of the safety profile of the investigational vaccine.</description>
        <time_frame>From Month 25 up to 6 months after CYD booster injection (either at 1 year or 2 year) (i.e., up to 30 months for Groups 1a, 2a, and 3a and up to 42 months for Groups 1b, 2b, and 3b)</time_frame>
        <population>Analysis was performed on SafAS.</population>
        <group_list>
          <group group_id="O1">
            <title>STAGE-II Group 1a: CYD Vaccine + CYD Booster Vaccine (1 Year)</title>
            <description>Participants from Group 1 who received vaccination in STAGE-I; and were seropositive at Baseline received a booster dose of CYD dengue vaccine in STAGE-II at 1 year post last dose in STAGE-I (i.e., at Month 24).</description>
          </group>
          <group group_id="O2">
            <title>STAGE-II Group 2a: Placebo + CYD + CYD Booster (1 Year)</title>
            <description>Participants from Group 2 who received vaccination in STAGE-I and were seropositive at baseline received a booster injection of CYD dengue vaccine in STAGE-II at 1 year post last dose in STAGE-I (i.e., at Month 24).</description>
          </group>
          <group group_id="O3">
            <title>STAGE-II Group 3a: Placebo + CYD + CYD Booster (1 Year)</title>
            <description>Participants from Group 3 who received vaccination in STAGE-I and were seropositive at baseline received a booster injection of CYD dengue vaccine in STAGE-II at 1 year post last dose in STAGE-I (i.e., at Month 24).</description>
          </group>
          <group group_id="O4">
            <title>STAGE-II Group 1b: CYD Vaccine + CYD Booster Vaccine (2 Years)</title>
            <description>Participants from Group 1 who received vaccination in STAGE-I and were seropositive at baseline received a booster injection of CYD dengue vaccine in STAGE-II at 2 years post last dose in STAGE-I (i.e., at Month 36).</description>
          </group>
          <group group_id="O5">
            <title>STAGE-II Group 2b: Placebo + CYD + CYD Booster (2 Years)</title>
            <description>Participants from Group 2 who received vaccination in STAGE-I and were seropositive at baseline received a booster injection of CYD dengue vaccine in STAGE-II at 2 years post last dose in STAGE-I (i.e., at Month 36).</description>
          </group>
          <group group_id="O6">
            <title>STAGE-II Group 3b: Placebo + CYD + CYD Booster (2 Years)</title>
            <description>Participants from Group 3 who received vaccination in STAGE-I and were seropositive at baseline received a booster injection of CYD dengue vaccine in STAGE-II at 2 years post last dose in STAGE-I (i.e., at Month 36).</description>
          </group>
        </group_list>
        <measure>
          <title>STAGE-II: Number of Participants Reporting Serious Adverse Events Including Serious Adverse Events Special Interest Following Booster Vaccination With CYD Dengue Vaccine</title>
          <description>An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE was any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was congenital anomaly/birth defect, or was an important medical event. AESI were AEs that were considered by the Sponsor to be relevant for the monitoring of the safety profile of the investigational vaccine.</description>
          <population>Analysis was performed on SafAS.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="59"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="53"/>
                <count group_id="O5" value="56"/>
                <count group_id="O6" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious AESI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Unsolicited non-serious AEs: Day 0 to Day 28 post any vaccination SR: within 7 &amp; 14 days post any vaccination; SAE: up to 24 months for STAGE-I); up to 6 months after last vaccination for Stage-2 (i.e., up to 30 months [for Groups 1a, 2a, and 3a]; &amp; up to 42 months [for Groups 1b, 2b, and 3b])</time_frame>
      <desc>Analysis was performed on SafAS. SR was AE that was prelisted (i.e., solicited) in the eCRF and considered to be related to vaccination (adverse drug reaction). An unsolicited AE was an observed AE that did not fulfill the conditions prelisted (i.e., solicited) in the eCRF in terms of symptom and/or onset post-vaccination. Reported AEs were presented as pre-specified in the study protocol.</desc>
      <group_list>
        <group group_id="E1">
          <title>STAGE-I Group 1: CYD Dengue Vaccine</title>
          <description>Participants received 3 doses of CYD dengue vaccine 0.5 mL SC at Day 0 (Vaccination 1), Month 6 (Vaccination 2), and Month 12 (Vaccination 3).</description>
        </group>
        <group group_id="E2">
          <title>STAGE-I Group 2: Placebo + CYD Dengue Vaccine (Months 6,12)</title>
          <description>Participants received a dose of placebo at Day 0 (Vaccination 1) along with 2 doses of CYD dengue vaccine 0.5 mL SC at Month 6 (Vaccination 2) and Month 12 (Vaccination 3).</description>
        </group>
        <group group_id="E3">
          <title>STAGE-I Group 3: Placebo + CYD Dengue Vaccine (Month 12)</title>
          <description>Participants received 2 doses of placebo at Day 0 (Vaccination 1) and Month 6 (Vaccination 2) along with a dose of CYD dengue vaccine 0.5 mL SC at Month 12 (Vaccination 3).</description>
        </group>
        <group group_id="E4">
          <title>STAGE-II Group 1a: CYD Vaccine + CYD Booster Vaccine (1 Year)</title>
          <description>Participants from Group 1 who received vaccination in STAGE-I and were seropositive at Baseline received a booster dose of CYD dengue vaccine in STAGE-II at 1 year post last dose in STAGE-I (i.e. at Month 24).</description>
        </group>
        <group group_id="E5">
          <title>STAGE-II Group 1b: CYD Vaccine + CYD Booster Vaccine (2 Years)</title>
          <description>Participants from Group 1 who received vaccination in STAGE-I and were seropositive at baseline received a booster injection of CYD dengue vaccine in STAGE-II at 2 years post last dose in STAGE-I (i.e. at Month 36).</description>
        </group>
        <group group_id="E6">
          <title>STAGE-II Group 2a: Placebo + CYD + CYD Booster (1 Year)</title>
          <description>Participants from Group 2 who received vaccination in STAGE-I and were seropositive at baseline received a booster injection of CYD dengue vaccine in STAGE-II at 1 year post last dose in STAGE-I (i.e. at Month 24).</description>
        </group>
        <group group_id="E7">
          <title>STAGE-II Group 2b: Placebo + CYD + CYD Booster (2 Years)</title>
          <description>Participants from Group 2 who received vaccination in STAGE-I and were seropositive at baseline received a booster injection of CYD dengue vaccine in STAGE-II at 2 years post last dose in STAGE-I (i.e. at Month 36).</description>
        </group>
        <group group_id="E8">
          <title>STAGE-II Group 3a: Placebo + CYD + CYD Booster (1 Year)</title>
          <description>Participants from Group 3 who received vaccination in STAGE-I and were seropositive at baseline received a booster injection of CYD dengue vaccine in STAGE-II at 1 year post last dose in STAGE-I (i.e. at Month 24).</description>
        </group>
        <group group_id="E9">
          <title>STAGE-II Group 3b: Placebo + CYD + CYD Booster (2 Years)</title>
          <description>Participants from Group 3 who received vaccination in STAGE-I and were seropositive at baseline received a booster injection of CYD dengue vaccine in STAGE-II at 2 years post last dose in STAGE-I (i.e. at Month 36).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="348"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="348"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="352"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="62"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Branchial Cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Thyroid Cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Food Poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Food Allergy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="348"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="352"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Diarrhoea Infectious</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Groin Abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Hepatitis A</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pneumonia Staphylococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Viral Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Animal Bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Forearm Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Gun Shot Wound</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Head Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Jaw Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Radius Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Road Traffic Accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Thermal Burn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Intervertebral Disc Degeneration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pathological Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Rheumatoid Arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast Cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Papillary Thyroid Cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Subarachnoid Haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion Spontaneous</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="348"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Abortion Spontaneous Incomplete</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Threatened Labour</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional State</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Calculus Urinary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="352"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Renal Colic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Adenomyosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Bartholin's Cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Dysfunctional Uterine Bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Uterine Polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Respiratory Distress Syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Toxic Skin Eruption</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="352"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="203" subjects_at_risk="348"/>
                <counts group_id="E2" subjects_affected="189" subjects_at_risk="348"/>
                <counts group_id="E3" subjects_affected="182" subjects_at_risk="352"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="55"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="53"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="59"/>
                <counts group_id="E7" subjects_affected="20" subjects_at_risk="56"/>
                <counts group_id="E8" subjects_affected="18" subjects_at_risk="62"/>
                <counts group_id="E9" subjects_affected="15" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="133" subjects_affected="98" subjects_at_risk="348"/>
                <counts group_id="E2" events="114" subjects_affected="80" subjects_at_risk="348"/>
                <counts group_id="E3" events="100" subjects_affected="71" subjects_at_risk="352"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="53"/>
                <counts group_id="E6" events="6" subjects_affected="6" subjects_at_risk="59"/>
                <counts group_id="E7" events="9" subjects_affected="9" subjects_at_risk="56"/>
                <counts group_id="E8" events="6" subjects_affected="6" subjects_at_risk="62"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="31" subjects_affected="29" subjects_at_risk="348"/>
                <counts group_id="E2" events="23" subjects_affected="21" subjects_at_risk="348"/>
                <counts group_id="E3" events="34" subjects_affected="31" subjects_at_risk="352"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="62"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Injection Site Pain</sub_title>
                <counts group_id="E1" events="154" subjects_affected="109" subjects_at_risk="348"/>
                <counts group_id="E2" events="164" subjects_affected="114" subjects_at_risk="348"/>
                <counts group_id="E3" events="146" subjects_affected="97" subjects_at_risk="352"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="53"/>
                <counts group_id="E6" events="7" subjects_affected="7" subjects_at_risk="59"/>
                <counts group_id="E7" events="12" subjects_affected="12" subjects_at_risk="56"/>
                <counts group_id="E8" events="11" subjects_affected="11" subjects_at_risk="62"/>
                <counts group_id="E9" events="10" subjects_affected="10" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <description>Events of malaise that occurred after 14 days post-vaccination were considered as unsolicited AE.</description>
                <counts group_id="E1" events="170" subjects_affected="114" subjects_at_risk="348"/>
                <counts group_id="E2" events="146" subjects_affected="98" subjects_at_risk="348"/>
                <counts group_id="E3" events="148" subjects_affected="103" subjects_at_risk="352"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="53"/>
                <counts group_id="E6" events="9" subjects_affected="9" subjects_at_risk="59"/>
                <counts group_id="E7" events="9" subjects_affected="9" subjects_at_risk="56"/>
                <counts group_id="E8" events="7" subjects_affected="7" subjects_at_risk="62"/>
                <counts group_id="E9" events="5" subjects_affected="5" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <description>Events of myalgia that occurred after 14 days post-vaccination were considered as unsolicited AE.</description>
                <counts group_id="E1" events="143" subjects_affected="110" subjects_at_risk="348"/>
                <counts group_id="E2" events="126" subjects_affected="92" subjects_at_risk="348"/>
                <counts group_id="E3" events="112" subjects_affected="87" subjects_at_risk="352"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E5" events="9" subjects_affected="9" subjects_at_risk="53"/>
                <counts group_id="E6" events="8" subjects_affected="8" subjects_at_risk="59"/>
                <counts group_id="E7" events="12" subjects_affected="12" subjects_at_risk="56"/>
                <counts group_id="E8" events="9" subjects_affected="9" subjects_at_risk="62"/>
                <counts group_id="E9" events="6" subjects_affected="6" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>Events of headache that occurred after 14 days post-vaccination were considered as unsolicited AE.</description>
                <counts group_id="E1" events="201" subjects_affected="129" subjects_at_risk="348"/>
                <counts group_id="E2" events="190" subjects_affected="123" subjects_at_risk="348"/>
                <counts group_id="E3" events="184" subjects_affected="124" subjects_at_risk="352"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="53"/>
                <counts group_id="E6" events="11" subjects_affected="11" subjects_at_risk="59"/>
                <counts group_id="E7" events="12" subjects_affected="12" subjects_at_risk="56"/>
                <counts group_id="E8" events="7" subjects_affected="7" subjects_at_risk="62"/>
                <counts group_id="E9" events="7" subjects_affected="7" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Trial Transparency Team</name_or_title>
      <organization>Sanofi Pasteur</organization>
      <phone>800-633-1610 ext 1#</phone>
      <email>Contact-US@sanofi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

